var title_f1_10_1184="Type 2 odontoid fracture";
var content_f1_10_1184=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F81657&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F81657&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 528px\">",
"   <div class=\"ttl\">",
"    Odontoid fracture type II",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 508px; height: 353px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFhAfwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD2O2srdZi0cUY5/ujjmtaFFHAAH0Fc9pF35pYk4BPGa6aIYANAEqcDkmlVvmxkikH3aQjnmgCZWPYmpg5x944+tVFJHU5qQNkUAWNxP8R/OoZW4OSaRZOcGldNw4oAoPH5jYA4zViO3C/WpVTb2qZR0oAWKMA8CpsDNNXilzQAhApoCg0rHioHfmgCyMYoJHeq+7A61Uu7ny+QelAGmMUEj1rPt5zImc1KWO2gC1kU8YqrG5NWFNADjUTqCTxUgNIaAKjJtbinorZ5qbj0oAAFACn5VOMVFxTbp9qVWSY9KAJ34NKGB71E7ciqz3Aj6j/61AEOqzMg455rl9euAEjkbqp/OtDxFqUccDFHUtg8d6851PX5LiFgOVAIY+hoA4T4h6tPcai5hYFVbjFe6/s96o+p+H7szHMsQiRv/Hq+fLvDagEmTMbthj3+tfRXwKtoLbS78W4HPlFiO/3qAPiQs25uT19aNzep/OlYHceO9NIIOCPzoAXcfU0bm/vH86SjGRQA+Nju6n86uyykQxqpIA5PNUEHNSSNlSKAFa4c8EnFKk7DoxqCigDTh1CdRgSsPxrRsdfvLWYOkrDBz1rnAxFP3kmgD3nwh8T7oRJFcvvxwGPWvVNB8VCfa4lPPO0mvjuzuGilDA4r1fwTrpmkRWY71XHPegD6n0bVbbUNqkL5npXQKAqgLwK8T8M3jwss5bkDpXqugavFfwcNl1HIoA2Kge6iSYRswDH1oWdWjyeDXL+Pi1vYrdRuVZOcjqaAOvHPSiuK8HeI/tCR21xJucgY3Hmu1oAKKKKACmyOqIzMRhRzTLmUxR5UZY9BXOarq0TBlVxuAwwHSgDA8Taq0zsLVWTBIOO4qnaX7mxKyhVcZ21m65qgS58uOMkyNgGqGrytEoaB8ttwRQBafV990yGYbiMbfWi5ikurZCo3OO4rzjVrqaK4YnKsDlcV3Hg/VpmtoRcHcCO9AEgtJXXBRg45zW7oVuylflwe+a27Py54/l2E9enNSbAjHCgHHegBiRqh+YYyapamY/uyHIPSrN1Ps2MfWsnUJN+cnkHNAHMXtu088qEuETlSD2qikTxAqTnmt6RwRvAyfbvWTOztISgGPegDU026jilhIk3Ajmu6024WaAEMGB6GvHPDyTysFlBDK2Dz2r1jRbY21uo3ZBGaANofd60pFRxsCKlByKAGHrUZlGcd6Jc5IBqtgg9aALQbnI61bjbIBrOjJJq/F90UATUZyaYVBdWOcjpzThQBJmgmm5pCaAEdsVWZstRcyhaoR3AeVhu6UAXXfBFZGrXCoQD1NX5JB1JFYGtyoro5PfFAG3prboQwq4XG3ms/TpYxbqAe1TzToFPegCWK5TdjOK0I3DDivPp9W2agY2YAbsda7XT5A0KnOeOtAGgDmlzUamnZoAXPNIT3pDTWHO7vigCveDKiqsYw+KnunydoptuuTk0ASFQOTWXqriKB3PHFaly4RcnoK5XW9aszHJAZFYEYPNAHludRHimSaeQvDIG2oOQPSku9Gks9JurltzFm3496W41eKz1QFZUmh39DwVr0rULW1l0DceY3UHIoA800TRYdVsBLMVQ9Pu45r1T4MnZPrlsMbYfIUAH/AK6f4V5Hqt/JpbyN92BD8oHeu0/Zkv21G88XTuc5e2x/5FoA+dNMttNnuFSVwMmtK90exe68uF43THBFceg8ouzZ3c4p1pcy+erK7A9KAOl/4QyWdv3JrO1XwzcadEWchhXT6TqU62wDE+1P1G5ju41WV846g0AecrEQCTULda6vULFJFLRgD0xXOXULRyEEYoAq0UEYJooAKUU2lHagCQdcd67zwDGfPSUnnpXDRrlhXZ+E5hHtXOPmzQB61Yap5MJTdyT09K2vCPilNN1BzczbY5SFGT3rgGuljTeOvvXIa7qrm7iUEqQdxx2oA+t4dQkvZkaJsx1paxFHeQJbXB3bv0rzL4N6295ZRLcMGYDAJr0DXbloBvXlyeAKAKWl+FYI9Ujmjkc+WecdDXe1k6HIHs4yo+cjLVpvIFTdnr0zQA+gkAZNJnp70kmCrZHAGaAM7XL2K0gzKwGQcZrzi6vEaZyi8M3GfrXY+LJLW8tRbyHa3UN6Vx10kdra5kCkL0NADdQtreS4inLZZeQtYWqQRq7ytJiN+3pQdS+1XAU/KFXkg9Kx9QvRPE+1soh5FADLy0t79kZFLkcGtPS4VgZUJwegA7VkWF4sCYBwp/M1paVM019lgQq85oA63RGlS7XGeuK6y6UFdzcHtiub01d86MDW3ezhE5PFAGTqc48oqpw68/Wsq5fzo8/xd6mv50bdnn3rMa5AUgkfXNADZWVYsdMcGsyRcuSKmllWQMWPB4rPeYqxC5xQBkeG9XjsZ1Mkm9SeTivX9E1O3vLYPE+a+ZNO1aAJjeW2Hniu40DxP5JVFbZvIAANAHsdxqLW06Z/1bHGK2bW5jmTdGwI+teReNfEJsdKtrhs4OPmFUPAvxBikvGgeUAsQeT1oA9wfkZFVJG2twOKSyu47uJZImDAipmRXoASNhxV2PgCs+U+Up2jNWLSUyAZoAu9qKaKdQAtNc4FKailfANAGXrN3HZWks87BUQEkmvIl8evLe3HkYWJTwTWv8WdWldfsEJbDfexXiepNJaqwTcGbrQB66vj9DIqM/1OaXV/EaT2wkEnGcgg14E0t7JIAu7mtJV1BbYK8j7R2NAHq8vjqQAJbS7ccZ9a0NK8azeaouWDo3evFLO3vJJTsDk/Suu07Sb6SEO4dQO9AHp2olb6XzrZgd3Nd14SupG0uMTDDr8vPevNfCSrAVjmkLMeMGvVtOhWO0XYO1AGzG2RUmapwSHjirQNADzTSe1GaQnigCCWME5pGdYl68U+YgKc8Vw3jnxZbaNaON+6Uj5UU80AWPGPii10uylaWZUGMZJr5e8ReKbuW+l+yXMiwFiVI61L4w8Q3mtXLm4YiPOVTPArjbljjmgDasNVvLq9hjDl3dgPqa+kPEeptoPg2wEpz8qq59OK8I+DukHVPFEcsi5gtvnb0z2r1j40XIXw/HFnpzigDzDxXqzyQTytKHjb7pr039jG4e4HjDecgGzx/wCR6+cNWuJGtwhc7M8DNfRH7E/3fGX1s/8A2vQB4bewBZCo9as6fp6ovmFcn0NXLe1+13rnHTmrs6CFFRepoAitL8ZZGUIFHFVZJjJ8ynP0qDUmWGMgfeNZ8M0kJDKfwoA3bWVVgd5M4FZ13FDMp2csaswz+dCwI6jms+VSpbbmgDGnXa5FR1YukYuSag2mgBtSgYQetMA9akPQUASocYNdD4dcrl8jOeK5cHnArpdAXALAZNAHXNM0g+fhFG44rirqU3N88h6FuK6DWr1YbIQRNiRx83sK5XzGDgLQB658Mtd/s3UrdHJEWMH619J21rHrNkkiHBA4NfGmj3RgUMSd3avqP4Ha9/anh8wyNmaE7W/pQB32lWZtbVEcfMPerNyVICt3qXeM4zk+lDIrHLDNAFKCOcXPUiNT371Lf7lQPuwi/eHrVqqeqQNNZMicUAcLrFtcahdq8B2gt07EVgeMleBFt4/vsBnFdoiixmVOsfU57VlatNp9/qSKz7XXABHcUAeKa3cXFi/lx7/Mflh7VX0u5Z5mDqeR8wPc161qfhyG6vPOVUYHgMRXAeJdJubSRobWMsC2Tgd/WgB1nYTXY81l2Rg9a1kmhiURp1H61W8Pfa1sHhuFbj1HNWLfTJZrgv0jB6kdqAOu8MsTEZXPyrwM1Jql+q7iW49KyrjUYrKBY0O1VHTPeuc1HW47hW+b/gIoAsXepklliOR71m/amZjuNZRvxubcOM8c1G1/EGIBoA3PNJGM9O1V8liT/WqMN4smMNz6VIJ+uRzQB4XYamlteSeaGZCT0rWsNZd9QQoNqg/KK4+5OLmT2Y1esJsOjDsaAPpO4sF8SeBpIVwZ1TenuR2rwSTztPvGQ7kkjb6EGvbPhzqgXS4gz8dDXI/GLw/9nuhqlqn7pzh8Dv60AaXw1+I0tjdJa6lITC2BvJ4r3vTdXtryFXgkVlI4weK+K7eTA966rw/4i1KxZEtruRUH8OeKAPrc3MbjDY+tW7ExtkoQa+cx4u1aa2wtyd2OoFdd8F/Eb/bL601O7LTS4dDI3p1FAHtQp1ZTazYLMIzdRBz23Vd+0Jt3BgR65oAnJ4rO1E/LwwArI1DxXYJK9rFcxtcDjbu6GuX1d9TnBMbuUPYGgDO8TR2zSyH7QjSk8+1cZdWlnJ8pUOw6kDNP1qKfey7WDk8mn6BaeXdAO2c9c0ASaVaacSd8IBHAbbSa7ZwpDlgoj7YHWus+z2TQYwgPfFZGsW0X2ZlDqwA4JNAHm2qa9FokWLePdO3c9hWNF4+1d7hTGQAP4QODU2u2du14ymQNz0zV7TPD1u6qyAHvQB23gvxe1w0b3tnGuMbnB/pXtGjeIbW7jVIgc49K8O0/RbO3AeadUUc9a7Hw7rmlWcm20L3DDrt5A/GgD1ZbrdnYpP4U3+0UgJa4dUT3PSuNm8TzSxEW0YQe9cnrGrz3LtC7FmIOeeKAPZ4b6GaESwyK8Z7g1xnjH4laV4ZvI7e5fezDJCnkV5bfeJbrwroxSJ3LSfd3HivFdd1K61PU5bu6kaSR+SSaAPpHWvjFYTWSrpvzzyHAB7V5r4h1CW+keadyzvyTXm2lu7XEeeBuFegXlvvg+9jIoA4zUGzKayZgXbaBkk4Arc1S2KsWDAmtXwpoAuLmK4uB8oINAHovws0xdC0KKSXC3F025vXHpWb8W9Q+0aXIQ3G7aK0p7/bdw7MCOBc4/CuE+IF0X0m3XPMjZoA811NvlQe1fSP7E33PGX1s/wD2vXzXqZw4HpX0p+xL93xl9bP/ANr0AcZpGnR2tg8suNzcms27VZ3JjU4WvRNL8MS+I2kt7ZkgWOMyO7g4AFee38jWkM0UODtyMjvQByt+GkuDnoKjUAR8d6ikuWkOcDdVi0iMhBNAEtsrJk+tSiLg56mrEMG2plhyaAMXULc7VYCstkxXXXlv/oxB5xXMXGFY49aAKuOaYx9OtSucIfeoCc9qAHwjdIK6nTl8qEY69a5m1B8wV1dv8kC5HOKAKV85BLSHLmqcS5BP8R6VfFrJfXYjiG854Ar1vwb8L/MsBd3xHnN9xCOBQB5fa2syIuQcsMgV678L9aOh2zIpILfMxqteeF5LK78u4iTcDjit/TvDKGHfHkHvxQB6lpviSK6slkjbLjr7V01pqEdxAHXv715F4dtnsppY3ZiGHArrdHuzDGd/boM0AdFd65HaTpDIRuY1oRXXmqJFZTGe1eb+KS5b7SOvUU3QdbuX3+duK4wDQB399Z21/C/VGI6iuFuPDFxBdmdG3sDwR0xW3BrJxtLYFLJqgiTcDkdxQBUt4HCIJVKt39M1LdQROOUX6kVYt9Wt2XEoUbuQSc1Uv5owpJHB7igCu1rZoAzKua5vxDrMFrFJHbqM4xkUus38cUbOXGAPug815nrmozTzMACqHoM80AVNU1u5uLg5OFBxjNUnv/7zEE1SuJOuetZ00pHOaANd7jcRtJpRPnHNYQuCO/WpopSxBzQB0drOxPNa8SkpljzWFpSPLIqxqWauytPD11NAHbIJ7UAfMDsWdie5qewf97tz1qtnk/WlgcpKD70AeyeB7tl0113cjpXoJkh1zRfIuFDpKm05ryfwVcqjqjHiQV32gzNCtxb5/wBW+5foaAPJtf0a40fUZLeRTsz8jeop+kwztKNiM30Fer+INMh1u1KkASDkN3BrhLQy6XemJwFKNgj1oA3NJtjCP3wOSPSqFvJLDrsZjBHzYOOOK6dL2IrGQA24Zx6Vkyahbrf7WQKc4BxQBt3TyWt8s8bsAwy2T1rdtfFU8dmYjO4Xpya5vWpP9EiZcjP61lWW+8+Rs4BzxQBt6josWou10shR/vKwPOas6Nq2r2EiwSXDyIOBu5rb8M6VJPabSCcdPpUsXhyW3ut0hGzPTPagDifG+vXVm+47fnrA8K65cX2sIskhKegrpPidpkWyMgjapwa5Dw6U02fzlTNAHoQunjYgZIzVS/uDcI4+b5Rmqa6/b5DFfnPYinwanFMJA6hVYEUAeXajO8moSEA8Gur8OW91NZO8bSA+1Zl3HbpqUhbBBPavRvBP2b+z2jRlJb3oA4k2k002byWTaD90mux0OH7Pbn7NhVQZIx1rqofDNne8zqPqDWvF4btYrZooWx9aAORt9ZYsYnAXAwDVKWUiUMTncas67pMtg7YU7c5yKzrZvPVVcfh6UATeMobW802EXAXCjIzXkV4kUUzBFXAOAa9P8Zw7LS3Eh/h4rzLUYcOwGNtADNPiWW4UlgoBzXdXEZNtGykFdo5rz22cIAA46+tdjZzl9PX5wwHoaAMq9haW6SJOWZsV2sAWx01YxwQK53w/CJtReaQfKnQn1rUv7wPKwU5VRQA2W9xa3UpP8JrlvGFyJrazTrwKm1G+26VKqn5nbn865+/nM0sCHkDBoAwtW4nxX0r+xL9zxl9bP/2vXzTrBzdN7V9K/sSfd8ZfWz/9r0Ac7N4u1PS4pvsVyI4pV2SKAPmU1yeo6xZmzlKA+cwKgV7h8RvhdpdtpN5d2fmwBI4hGpOQ0jNjFea/FP4eW/hy+021sDM0j2weZ2+6z55xQB5hax+Y2a2rS3IxiksNPeLduAOK0ciMYPBxQA0pjFSqpxgfnSJjdkdDVmMhcnjHagCncnajKTniuPuiFkbPY8V1N3Jw/OBXI3zZl46UAV2csaSkooAv6coaZc9Aa1rm46InU8Vk2LbQWqWOQmbeTwDQB6J4Nto7ZBOwBfI617d4cvJ28o7v3TLyD2ryX4crHfny8ZXH5V6a8v8AZlsGz0X5aALniGUPqYdQGEeNx9au2GoRvEEUAE+lc3BciQHuW5Oaha4ltJA6KSvY0AdXdTxQSiV22kdfpWdeaqplzHzgZBB61jSa1DdqUkOGIwQa46bUpYbtkjYlAccdqAO5fW3aQCZt8Z/hPaga3HgEt5YFcTLrUaod6kkVyereIJ3couUUccUAezW3iWzQlZJOh6mrba5ZXUZRJlVvY184XGrXO7dHK5FWtI1tzKA8hVh70Ae33eoOrlEcMoPHPSp7HVr3y/Iu1yvZhXmdrrUgzucEfWuq0bxNFLAIp13FeM96ANm+hSdtuSG7Z71y+rabNk4Xkeldta3VleRKoYbh61dj00yEmEKR7mgDxW9sbgEgRMT9KzjpV5KcLA3PtX0SmkDbumjiP4VE8dlAT/ois3qBQB4JaeFtQmYZiI/Cus0XwDNJhpw/PUdK9Gk1GCD7loxOeirVWfWb5hiG2WIerGgCXSPDljpiKzAb8dK1BeQpwsSke4rm/wC0miybuYMfQVEfEdohwVGaAPkbufrTQcH3p2eTTO9AHbeHrry7aCYdVbBr0axu1a6jkVgPNTGK8k8PybrSaP8Au811Gn37eXbuGO6M0Aek2t1ibB96wPGEFuxjvIzll4cCqY1NzcAbsZqeGRZleKTBDCgCpYXsTMp3YPpWXqOopDqJZxlQ1QXUDWd20Z6A5B9qxtTlaO5JJyOvNAHr92n23w5aXMOWBHIFX/CujPLhliOG67h0rH+HGsRXWkJA64KcEdq9OXVrTSrAOdoYDgUAacEUel2YzhcCuA8XeMkglMVsN8nTiszxH47N3I0NtlmPGBUGgaXBcSCe++aVznB7UAcpqep32pOxuM4PRccCqWi2Wo6jq1tp1hbPPc3EgjjUDqT6nsPU9hXrMml6csmSIxjtWl4RuING8RpeWrwLHFE8kxZAcRKNzYPYkDAPvQBxvxc8NR+G9U0XSLJBI0VgslxOvWSVpH3E/kMe2K5ExXMVvgRsWJ6mvSPF3iaDxJqyX1wIUkWJYyqNkcZ5H51lC9sGO12XGMUAebSWVxI7NsIqxa2upw/NbmQD/ZNehwR6XcZVGUAVr29tZQouApFAHFaV4h1ewA81nIHZhXe+H/G8UoAvAoJ61Fc21rcAqI1YfSuO13wnPK7Pp0jRN12npQB65PcabqtuSrK4x09K56fSbW3l81GAA7V5BFea94duA0yS7AevUGu10zxTBq9qQrBbgD5kJoAw/ijqSFreKJ/u5OB3rzG6uZJM84rovG0sj329z04rlJH3KTQBSLHcck9a6HTpnSyG1iCT2rmXbLGuj0ACYID0HNAHVWlw9vYbS3zMMmqkl2VVlzye9E7b3CDtxVK5wrYyMHigCnflxaEsOrcVl7i15EB6Vqaw/wDosajrWPHIPtyHtigDM1Q5vHr6Y/Yk+74z+tn/AO16+Y785u5PrX05+xH93xn9bP8A9r0AaMvxPv8AXvD99pGqW4a+eRfKkjGAoBzz78VFrN7eanbJc6zMJDDHtUkY4rOGnw2l3POVChmxmsnxDqRls2ghbIHGaAOVvriNWYx9CSTWeNzPk0+SM7iXOTS7toKkjIHBoAXzRGmCBVS+vwkRVSNxqrcznJJzx0rEu5WLk560AaTXnmRspPJrHufv0sUn51FK2WNADKBRQKALkZ2xH3p6t2quG4A9KeGoA7X4cavJputAr80ZHK16hqevHUZVSMBUjHfua8O0C4MN6jA+xrv7AtLISHwhGeTQB6NpKGS18zcN2MCtWzjMreVInyDviuT0m/k06IIBvDnkjnFad3qNzHFtQtlvTsKAKniHTIrWR5ImO7PArl4bOd1MuxssT/8ArrtY41lt/OvnJBHA7mqsD+ZchIYMRIOcnoKAOBuo5HmeMAg9zXPakvlFzIRgV6tqOkRSb721YMCDlAeRXk/iVGF4UIIAzQBjPIzYCcDvVGSQq/HXNNmmMchCn2qOR93PegDQt9YmiG3OQPWtbT/EPlSBuhrkmOGNICe1AHrth4mWSMMG2v7Vu6Z4vvUkUJMCPQ14ZDdywn5HIq5HrN0hBV8H1oA+gG8YXfl5mmAHfFULv4ixwLsRfMI4zXh82t3kow8rEfWqct1LITuc0Aev33xSYZCqo+lc3qHxJv58iMBfc156WJ60maAOku/F+q3BOZ8A+lUP7YvpCWa4kJ+tZWfepIj8p+tAGT3P1pp604dTTT1oA1fDshW7ZOzjFbllJtcp3Brl9Ok8q8jb3xW2z+XfEg8MaAN6O4YSIWP0NaVregOpzgg1hK3mQ8dVqxandz3oA6HV4lu7YSx43jmuD1tz5oB4IHNdrZXBU7G+6e1c94vsx9oDxDORk0AafhDUhplq0rNgYzWpLrOoa/dCC1Dsh44rn/Cvhu71jb5ztHbj9a9q8JeH7TTLUIqAHHJ7mgDntE8NLZQiSfD3DdT2WtGdDB80bcLxxV7XNRSJxCg2jp0qlDG9wpVclgOKAMa7vGMmNxB9KkvZns/Bt5cK2J9TmFlH6+WmJJCPq3lD/vqoNQsLkTMViYHvxVnxNF51vYWll80NnbIgbBG6RvnkPP8AtMR9FFAHFeU6R5bKn1p9taTykqoZn7YrT/sqaUBZ5gqr+db+k29tZfMhLSEdTQBnaVo92ELFDkDpnk1dieeKTbIG+npW/pN+kJLEZIPU10Tx290qzLEhVhzx0oAxNKV2jXAJzW9HAxxvTtWro1rChGFGO3FO1dhbR5RevU+lAGLPpsFzGyyqpPuK8l8e6fYaTciaymEFyvOE7/hXp7358wM3TOM15/8AEHRBfz+ejc44xQB5lq2si+gIlX973PY1iBiVwMnNaU+jXUl40SITt6kDNetfCL4WJqZj1PU5F8mKTmAry2P6UAeFyIyH5lI+tdNoDrBBk9SK9d+M3hKwmvZP7PtkheJAfkGATjpXjduhiuUi54PNAHQ2oaRncg4xVPUAC6JjoetasKYj2qMcZqjPCXuAp4A5oAy9U+6BjoMVgtlLpT3FdPqkO50UDvg1zOoAJesPTigDMnbdM596+oP2JPu+M/rZ/wDtevlxzlj9a+o/2JPu+M/rZ/8AtegDG8Q6i0ySLGTtznNYJkD2vJBz3qobppWaMkkd6jE3lxlGGKAKt1yzY7VnT3CqcVJqN5sG1SOe9YksjOetAElzMGzg8VmT9T6VO7ZGO9V5elAEanFIetFFACUo60UCgBxPzE0oc5plTW8JlkUDuaANbw/ayXNwNqnHTNdn/YWpumEPHbnFT6ba2+jaPHIwBcjP41s6TrkUq5K9KAMnTrvU9MuUWaNnVTyDXZWviS2vE2ywrHJ0I9a1NPtLe+Af5c46Eda5vxloktkfOsxhW9KAOrs4obwhcqsY5AJqv4omFhamK1UYYfMQK8zsNVvLSZczMMH7rGuwm1qK5sCJ5FJ20AZVnqz2kyx5xGxwQTVTxLpSanHM9swMq+neuYvL9XndQ/QnGKv6RqEsLhom3DuD3oA4G7tZ4bh0kQhgcHiiK0nmwI42P4V6Vdi3vJwzRDzP4uKW71Cy0mD/AI9UL44zQB5rcaddRDMkRUe9U2UqcGuj1jXHv5clQoAxgVhXTBsEdaAIKBSUtAAaKKSgBaKOwpKAF6VJF90/Woqli+6frQBldz9aYepp/c/WmHrQAqHawI6g1th/OaFx1PBrDrT06T5QvoeKAOmtIiqkt91hmrlhGrSKP4c96W1QNbIT0p0f7mcLg4JxQBpvFtkUr16GopUimvwtz/qwOR61OJSzx4GSBk+9Ub2JpZfMQHk0Aek+F9NnuRBJaxKlsODivRz4duDaqVIUvxjvVT4b2HkeHLQOMuVzzXoEKs5G4DaBxQB4lrmjyQOzuQdp5rS8ORRYWTbkYrqvG9mIrO5eOHACFg3rXmugeJ4TAYSAkinGCaAOk1+SIvtQKre9cpqG85MYq3d3PnOXLh2PPBqtId0XPWgDG8qRnB5GTWlHalYCeA3aprYea4RY8k8k9hWtHaxTuiM4ULy3tQBj2tsUkw2TuFbdjdSWc4jdCVPBGaif7IZiY5hwcDnFRalqkFvbgROhuBwC3SgDr7G7+zFWkyI25Ge1M1bUVlOYiGQ9K4S4165ltUilKE4+8lati5lsI3bqBQBYmkjYnPT0qOW3t57fDOGPpmqd3Ku07e1ZB86Vz5BYMfSgDpvBdjpdjfyzyRpL8+GDAHFdl4mv7eGztzpbrGx5Ij44968ksNM8RWd954sriSGc4BUZBrd1CK+sot92jKhHPtQBduZ11FpfNfzJCOSe9eO65pX2TWLj5ThWLDHpXpulEAO6t1rJ8R2QuGaXb8xGOlAHFTzGO1XpyMZqnbneTITyKt6tH5MflkHg96pW3EYwuKAFvFBUP2Ga43USDcu1dfeZ8krntmuL1AlZGHfNAFGvqP8AYj+74z+tn/7Xr5br6k/Yk+74z+tn/wC16APIkvCLkkD5c/nUN/qBccHGOlZU11gsENV2lJ75NAEs0xc881HuxURY5HNITzyaAHNxz3NQSNmpSwqBzlqAG0UUUAFLRRQAVsaHEJb2FD3YVj1oaRcGG9ik7qwNAHo/iwKtjbqh+UDFY2kO8cgXkhjgUus3kk9pvHQ8isexvnil5JPPAoA9o8LTMskanJDcEntXS+KYkk01SOc8c1574Z1yIJGsxIK85Peuw1/VI20UOjZ9KAPJvFUP2aR5I88c1ysmszKhVWNdpq9xHexsu35sV51qVs8ExyOM8UARG6ffuJOTV+x1R4HU5yBWQaBQB614eeDVYjLGR5oXkVxniuaR75lOdqcCs/w7rU2j36Tx5ZOjLnqK6TVtR0jVUMqnZI3JB45oA4o5OSaic81bujErkRnIz1qkxyc0AFFFJQAUUtJQAtFFFABUsX3T9ahqWH7p+tAGV6/WmHqafjk/WmHqaAD6Vc01sTgHoapiprVtsymgD0nRNstrsJ+YdKtXFsPOXoM9z61i6DdEBCpFdLfkGNWUdgSPSgCnwswzxtJH41s6FbRzX5WUblJBIrm7iY+eGj6Hr9a7rwXZia5jmY53AZoA9k8PNstYkA6AAD0rrYTtQA1yWhrtnToEHSuoDgYz0oAZrGnx6lZPbysVRuCR1r5t+K/hUaHei50138tm2sO+a+mnmQISSBXjfjwnU777MBuKuWPFAHk3h3UZoy0FyzZPILV1A1IKMgAgDHNR+IdE+y2ySRpmbHXFclcwXJDK0jfh0oA6F/FkVoXU8v6LWVeeLribd5PyA8YFYQs3TcWUH61EtvskysZOe1AF6z1O4aUu7uVHvXR6Raz6rvnk+aIHAU1j6bCHlRZFVF6YNdbJfW+l2aRwsApHJoA17Hw9a3KJhWjYejZFalx5Wnx/Z0VgAOGNcho3idkvF2Z2Kck9jUnizXZrxvLhRkbGd3Y0ASX1yyu2WwOtem/DfR7K4tkuZYw7FcjdXh+hW9/e6rBFcByjOAc9MV9QeG7FbGwhRVA2rjigDXWJEQKqgKOgx0rjPFOnJcmUbcqwwa7Rn+Q8Vh3UbSFieM0AeM3Ef2CZlUH5DjAqzEEu4zkVoeLbQxzySYBG7nFZenOnlEg4INAHKeM9N2hSo6nrXNRwFJdhHAGK7bxDdrK4VjwDXJ4eSfdjjPH0oAzr+IgNxg9K4rWotkuexr0PUFDRkqOa4PXmBPvQBid6+o/2JPu+M/rZf+16+XK+o/2I/u+M/rZ/+16APnpzhj65pucmmuRuP1prNzxQA/djNG4etRk0maAJGPHFRk5pKKAFpKWkoAWkopaAEp8Z2sCOtMpaAOusr2OaCKKY/Kw59qr/AGTy71myCmcrWTaSgFQx4rrNG+z3jKrkE9qAHabFNcXsccW4A8cV6HrGmzQ6ErKzEYAx61U0G0t7VxKVHHAPpXWapcwjT0iJHJBGDQB49MzxOwIOfeqN3BHc/eILV0XiqDbKzxj5a4m4nljfrjmgCvdaWVJKYqqbCU9Fq615Iw5Ip8Ny+eSMUAZrWM69VNRNC6deBWpeXjcgGsyd2Ykk0AQnrx0pKDRQAUUlLQAlLSUUAFLRRQAVJF90/Woqlh+4frQBldz9aa3U0/8AiP1qNutABTlOCKaKUUAdX4Xly+09BzXazK9xaI+MdjXEeEcCUFh1OK9WtLVWtjhflIoA5KS3YAZXnNeleA1VLNCw+Yc1zsll5hKgdK6HQFMDJtGMdaAPS9KlyATxjoK6K2k8wYNc7oyb41J79zW/bR7R9aAC8kCRnmuLXS3m1G5uG4Rvu8V2V5FvUjvUf2dY7VVx060AefX1pLNHNFPD93o2K4bU7CKNiNpHPXFe9CGKSNvlB4xnFeeeL9E86MtEu0hucelAHlF3aCN8s2QelUZHRSEjUBicGu2vPDqNCCrMCFrP07wpNLulcDaM4oA52WKOCQnzAWAxirUEa3rGJmDI4xjHIPrWjfeH7h5ECJzjHJrovCnhKdJ1kuOnUDFAHHaRY/ZxLv5XOK6GCO31CBETBlU4xW94i022sYhDCoBY5NM8JaMJb+OQcIvJ96AOj8H+GEM0ckh+aPkivUIMBQB0FYekW32dsjuK3IlIFAD2GQcVQuAFJB71eNU7kZzQByeu6YlzG+R8prg7m0FqGAHtXrN0oMRBAxiuJ1SzDs5XHGaAPKdWVxNkcheTWQHaN2I7dK7HV7ParkDknvXOXluyqQq4LGgCoFMlrKxxgKTXl2szeZduOwNes6jA1rodxJ6oRXjUzFpGY9zQAyvqP9iT7vjP62f/ALXr5cr6j/Yk+74z+tn/AO16APnNvvn60lK/3z9aSgAoopKACilooASiiigApaKKACgc0U6MgNk0AWII84J6CtG11E2nEIGfWsxpSzAdB7VatYGdgFUnPtQB3Hh/W5ZFQOCy9xWjqGqMk0cUUp8lvu7v4T6VY8A+GxOrNMcd8VHrmlra67JbOd0bjIoAilkmljKTrlx0PqK5fVLZTI2VxmuxktpBblTkyxDg/wB5axNTtxKm5SN1AHFyR7cj0pqkA471p3trgMQD61iyEhjjPFADJyQxqFjmrDKHGSQDUDYFADKQ0p60lABS0UnegBaSlooASlFJS0AJUsP3T9aiqWH7p+tAGfbwyXFykECNJLI4REXqzE4AFd38W/hfffDk6W11fRX8N8jjzIU2iOVCN0Z5PTI5478cVj/DLV9I0Dx3pWr+IYbqfT7Gb7QYrZFZ2dQSnDMowG2nr2rsfG3xWsvG3gTU9K1rSI7PVv7QF/YSWMZ8rLEiTzS8hIJBP3RgnHAoA8j70tJRQBsaBd+RcqrH5Sa908OAXGnxtnK4r53jYqwIPIr3j4Q3/wDaGmvC/wAzJ2NAG/DakO57DpxWrpNuVlG5e/U1NDBtlYMCBmtS2tgGV1U0AdHpC4HXit6LoMDiuf0xm3DI/St+J8qNtAD2QsamMIeLaR1FNQc9KtIOKAM+K2MUbK2Ko31ikiHIyD2rfZcrjFULuPAPB4oA8/1TR5V3iFfk7cc1WsbGeONkycjrkV2N0kzN8udtc/dQXRvHAZgp9KAM+e1EU0byIp5wSTWrd3EVtZDy2XeeFA61l65pFxNaAozBgRk1paNoRaSN52LYXoaAObGgXeqQS3UznzNx2j0FbPhDSprTeJGY/N6V2djZLCjR44qzFaCMnaOvNABYQnd8x4FaWMVBFhcDpU4zQAjdKoXLbScmtBway7hWd24oApXsyiFsGuYlnVt4OATxWlqqzBsKCc1jR6ZK0hd85zQBzWsRK0pKg8GuZ1KHM6qAfwrvb/TZSCyqeKxv7HmluVJTjPNAHE+PZBaeH2QHkpXh7da9t+LNlPHYyHB2ivFGRgelADK+ov2I/u+M/rZf+16+XiCK+ov2JPu+M/rZ/wDtegD5zb7x+tNpz/eP1pKAEoopaAEooooAWkpaSgBaSiloASnIu5sUlKhAoA14LSIKhYl2PYV0mkWyB4zgKlcdBdMhGDn2rcsbyZijbuB2oA9c8MB1u0EAYIah8feVDdpMSBKtR+FNURkjE7iJh0B4zVrx5p/2qOOVGBJ5zQBm2t9bXlurAhZUGfr7Vz+sqsCGSJtySHI9qzJXmsT8uc9Kpi/MgMUzcHpntQBMEyGcnI29K5O5dlZuOM1sXt20IZBxkYrBnkLHnpQBEzsaSkNLQAlFFA6+1ABRRRQAUtFJQAUUUCgANSw/dP1qKpYfun60AfSn/DLUJHzeKyfppuP/AGrVaT9lJGbK+MWUeh0zP/tWvp6igD5f/wCGUB/0OR/8Ff8A9upR+ygv/Q5H/wAFf/26vp+igD5hH7KQH/M5H/wV/wD26ut8CfAU+FLh5B4lN0rfw/YfL/8Aahr3GigDiH8ARu5Y35zj/nj/APZVPF4JRIwv24kjv5X/ANeuwooA5mPwmiZ/0o/9+/8A69WYPD4iXAuc+5T/AOvW7RQBkDRsf8tx/wB8f/XqUaXj/lt/47/9etKigDO/sz/pr/47/wDXpj6QGGDN/wCO/wD161KKAMUaEgGPO/8AHP8A69Rv4ciZt3nf+Of/AF63qKAMF/DcTKQZj/3x/wDXqSDQIogMSnj/AGa2qKAMpdGQHPmt+VPOlJj/AFjflWlRQBlrpCjP708/7NO/svjiX81/+vWlRQBlHS5MnFwvPrGT/wCzVC2iSk5+0xj/ALYn/wCKrbooA5ubwzJKebuL/vwf/iqi/wCEWlB4vYfxtz/8XXU0UAclL4SmcEfbrcZ/6dW/+OVCnguZDkX9r/4CN/8AHK7OigDyrxX8JZPENs0Mus28IbutgWP/AKNrgpv2X45T/wAjUo/7hn/26vpKigD5kf8AZVVuni/H/cM/+3V6Z8E/hSPhj/bONZ/tP+0fJ/5dfJ8vy9/+22c7/bpXp9FAH5pv95vrTaVvvH60lAC0HrRSUALRRRQAUlLRQAlLSUvegAopaB1oAcg6Vv6FtM6B+maxY1ycngVqafPHAwJPNAHosOlSXSqYs8DIIq7NdXVnFDBfFmUkgFqt+B9Qt7iJPmycYINbvjjSo7zRleFh50R3Db1FAHCazZxyIHHAPIrh9RheGTPYdCK7mxka4tmgnH7xP85rmvECKg2sCGzigDmNQlLyj0AqlL2q5f4jnwOmKqOysvvQBFS0lLQAUD3opKACloooASloooASlpKKACpYfun61FUsP3T9aAP0pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA/NN/vN9aSlb75+tJQAUlLRQAlFL2ooAKKKKACikpaACnqVHUZNMpVHzCgCUFmOTwKu2sYZwO9T2+lzS25ZUPqDWto2lKswac8Z6DmgD0DwBo8htd8Y5Pf2rqtab7BZbm5zway9N1BbKxhggIRjgcd6v+MUlm8MxysMSbgaAOTniCyi7tv+BD1FZPiK0huUEyjIIzx2qWzupICUmBMdRX4CblB/cyjK+xoA881iMi5OOlZ5GOta2psVum3Cs6cgtnGKAIqKKSgApaKSgBaKSigAopTRQAUlLSUALUkP3T9aiqWH7p+tAH6U0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAfmm/wB4/WkpW+8frSGgAPWijtQOlABRSUtACUtJRQAtFJS0AFTW4G4E9ah7U5M5oA7PSL6OS1a3Iy4Hyn1qazkkM3JwPQVy2nT+TMrkng10KXkRdmXj5c0AdNpeslJVDKGCnvXo+s6jZ3nh9Yw6qdobFeENO4GU69a6Lwxcz3CzeYWkVVPymgDdltlmX5cMD3FQXVmWtWjPTqtJApKbreQhsfdqS3v98oiu12sDgH1oA8312Forxww68isiUYwa7bx7axxSq8ZHTNcU7BgaAIaKKKAEooooAWk70UetAC0lFLQAUUUlABUsP3T9aiNSw/dP1oA/SmiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigD8035Y/WkpWPzN9aQ0AFJS0UAFFFFACUUtFACUvekooAU9KcnSm1JH92gCSPg1p2u6RdvPJ7VRhQAb5DhR+tWVvWQYhUIPXvQBtxwDAOMe5NbnhiN4bxSm0KTg81wzTSyN+8dm/Gt3QYpXK7Xbk9jQB1epI1reM9scgHJA7ipN0N3b+dFgsv3l7ita70c2+kJdBDnqa5a5V7Ym6tOg+/H6igDnPF8ry3CsSdu3GPSuWNdZrLR36l0GD6VybAhiDQAlFJRQAtJS0lABR3zS0lAC0UlLQAlLSUtACVLD90/Woqlh+6frQB+lNFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAH5pv94/WkpzfeP1ptABRRRQAlFFFAC0lLSUAFLRRQAU+N9vUZplFAE4ZpW9uwrWsLBriJiEYn2FUNNjV5hvOFz+dd/ZOttbRtDGqIeM4yTQBzcGkyFssMD3r0TwJodvvD3HY5C+tcncyGS4OCevHNdXol89pFHtxuYc57UAej+K4oP+EbdbdR8idq8a8/ynIZchuor1m0P2jw7dyTPuUoQfrXluo24Z2MfAHSgDltTi+yXyuoxE3IFYOp2/l3LbR8rfMK7TVoDNpo3Abo+hrntRg8yzhlA6fKaAMAoQMmmVYmXAqCgBKKWkoAKKKKACloo70AJ3opaSgAqWH7p+tRVLD90/WgD9KaKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPzTb75+tJSt99vrSUAFFFFABRR0ooAKKKKACiikoAWjvRSigC5YPtYHGT2rrrKZ3tACOBziuZ023LlDjjNdbYeWieXjOe9AFi3t4zcK+4MO49K1ZbhLcHbgsePpVSG2YMCvPGTxU/2J58M4ILCgDptM1cSeGLq1RwrMMEGuXa1nRC8TeauMla2NI0srbSIerAgZqjYF7eYxSZOD+VAFa1EF4rxKxPGCrDBBrn7mxZYLiLBwuTXZ32lEzJe2IxODllH8QrmtUvlWeRWGA5IPsfSgDgXUgsp5FVmUrwau3Eg898DjJqGTa/TFAFc0lOIwTSUAFFJRQAUUtJ2oAKKKWgAqSH7p+tRVLF90/WgD9KaKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPzUf77fWmmnN94/WkoASiiigANFFFABRRRQAUd6O9HegBafCu6QA9O9MqaB1QEt1oA17RmJATv0rorOILhp3CD3rlLe9MR/djk1q2cVzdlS4crnpQB1MmvWtunlqCxHHHepLHxCkjrmAkA461zt1pMwnUhGxiuk8L+Hp7qVMoQN2KAO70Sa0mRfkdH6+uapaxpscNw8q9+a77QNAtbaJTKAxUZNcx4lyt9O23CdAPagDCS6W2QPjOO1eaePkZdWM0Qwko3YHrXeamVVV5wD61z3iy0F1b2zgcAHBFAHmrg5PqajAIrpm0KRo2fOB2rGuLR4WIINAFA5zSEVZKe1RslAENFOYUlACUtFFACUUtFACVLD90/Wo6lh+4frQB+lFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAH5qN94/Wm05vvN9aaOlABQaWkoAOaKKKACiiigBKWigUAFPjQueDTafCSJBjvQBq6dHGsoBUEjnJrrrC9WOIrGRuHU1xoBVlIrotGKMknmrywwKANE6nLczEeYfTiuw8N6otqigE7z1J71xtjpzGXCY9a6ixsSqZdvlHp3oA9e8JXp1NMbQqovPvWLrEkV1ezIVAcH86veAlVNMuJVyGxjFV73SmmczxMVkU5oA5TVtNDxFSnHUGsOOxMtnKhBYIcivTV083sW1h82NrVkR6StnHcKckH9KAPNLyzZLVigPTJrlriDOQ616ebZZZ2iKnB4FcvrOjy207grx2NAHAXNoUY7RxVJ4yM8c111xZnJBFZ82nCQZHWgDm3jNQEYPNbNzZPH1HFUJIMdaAKlFPZSDTBQAUUUGgBKmg+5+NQ1ND9z8aAP0oooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA/NNvvN9aSnN94/Wm0ALSUUUAFBooNABRRRQAlLQaBQAtTWibpR7VDW1osUJb5iCxHGaAHxRAyAufoK6WyiiEKZIxVNbW3jw8so+g5q1BexxuBbwqPduaAOk0qBTgIrtu7gV0lvYyysqxjqeK5O11eaMAKM/QYFdj4a1GS4uIhJB36g0Aeh+HdPa20vK8Tqp47GrGmRmckuuD0YVt6NFG0CEAncNuMdKmttM+yXxYqQjHPtQBTtNMMVxvAwpGOlZmtWiRxyswAJzXoAswIWYdMZArzvxsJJD5cIIz9+gDhbgQo7MnY1T1FoLxFDYDjjPrWkdMkKknpUJ0ps/dNAHIX2lgk4Q/WsqbTSp4BxmvQZNPmXPylvaqF1ZOB9zrQB5zeWHJyMfhWHf2BXnFekXtpJyGUH8K52+smY89KAPP5oSGPFVXTHSuuvNP4OFrEu7QoeRQBjmipZIypqKgANSwfc/GoTU8J+T8aAP0nooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA/NR/vN9abTm+831ptAC0UUUAJQaWkoAKDQKKAClpKWgBVqaIsD8pI+lRIMsK2dMtI/MDSNn2xQA6ws7m5ddoOD612GmeHZkUM/LkcCo7R40UeQpB9eldVoEMk7guzjAz60AWNC8NS3AG9RnNemeFvB/kujyEcGsjw7aNvDAtk16foULKqZBJPrQBuaZp0dtGBjtVqa2SUDPBBqZM7RnrS0AIBhQPSsXVdDiun3oBk9Qa26KAOWPhODy8lsN6VnXPh77OeFDCu6prRq33gDQB5tc6WpB+WsmfShg/KK9Un06KRTgAH6VmXGkAZ+UEdjQB5JqGjLz8lc5e6MFz8gr2m80jKk7eK52/0YYPyc0AeLahpWBwnFcxqWmYDfLXteqaKTnjrXIato7KG+X86APF9Ss2jOQOKyHTaa9E1zTisbgjBribmAqxBGDQBnVPB9z8aidcZzU9uMx/jQB+klFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHwb8ErG01L4r6BaajawXdrLM4khnjEiOPLc8qeDyBXoHxJ03RdR+GmtX+jW+gXd5pWqqk1zpmnmwNrEx2KjAqPNO4gZHHOa8U0XVr7QtXg1LSbhra+t2LRSqASpII7gjoTWv4i8eeJ/EdgLLWdXnuLPf5hhCrGjN6sFA3H60AczSUtJ3oAD0ooNFAAaKBRQAUCilFADk61vaGS0pU9xWJCAW5rpfDcSmfO5fTrQB0lnbn5R716H4csisSkLnJ5NcvpVqshBDLjPrXp/huzU20YyNw560Add4dsUCI5AyRXc2VuqKpA7Vz+iwhVQHHFdPb5KgZ4FAE1FGOc0UAFFFFABRRRQAUUUUARSwJIORWRfadzkDNblBGRzQBwd/poyxK81yer6aF3Bl+U969du7RJVJxXN6ppW7dsHagDwLxJpQIZQvNebavpW1m4wa+i9e0dssSh+teb+IdH5c7efpQB4peWxTPFQwD5K6/WNNIDfL+lcoqhSyns2KAP0fooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA/Nw9T9TQKKKAENAoooAO9LRRQAg+7RRRQAUL1NFFACr1FW7L/WUUUAdTo3VfrXqfhn/VJ9KKKAPWfD3WL6/wBK762/1Y+lFFAEtFFFABRRRQAUUUUAFFFFABRRRQAN0NZ939z8DRRQByWt/wCrb6V5prv8f0oooA8213pJXnh/1kn+8aKKAP/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Type II odontoid fractures are the most common type and occur at the base of the odontoid process where it attaches to C2. They are considered unstable.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Mary Hochman, MD",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_10_1184=[""].join("\n");
var outline_f1_10_1184=null;
var title_f1_10_1185="Dog bite with fracture";
var content_f1_10_1185=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F68154&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F68154&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dog bite with fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 307px; height: 448px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This child sustained a dog bite to the foot, which was sutured at another institution. On follow-up, he had both cellulitis (Panel A) and a phalangeal fracture (Panel B), possibly complicated by osteomyelitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Ludwig S. Bites and stings. In: Atlas of Pediatric Emergency Medicine, Fleisher GR, Ludwig S, Baskin M (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_10_1185=[""].join("\n");
var outline_f1_10_1185=null;
var title_f1_10_1186="Patient information: Tardive dyskinesia (The Basics)";
var content_f1_10_1186=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?0/30/483\">",
"         Patient information: Dealing with side effects from medicines (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?31/34/32290\">",
"         Patient information: Taking medicines when you're older (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Tardive dyskinesia (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/tardive-dyskinesia-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H2368302505\">",
"      <span class=\"h1\">",
"       What is tardive dyskinesia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Tardive dyskinesia is a disorder that causes you to make strange movements. It can make you move your mouth, tongue, face, trunk, arms, or legs in weird ways, even when you are not trying to move. This disorder is a side effect of taking certain medicines. It most often happens in people who have been taking medicines called antipsychotics, which are used to treat mental illness, such as schizophrenia. Sometimes the disorder becomes permanent.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2368302520\">",
"      <span class=\"h1\">",
"       What are the symptoms of tardive dyskinesia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;People with tardive dyskinesia make strange movements that they can&rsquo;t control.",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        They sometimes:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Make odd faces",
"       </li>",
"       <li>",
"        Stick out their tongue or move their tongue around",
"       </li>",
"       <li>",
"        Pout, pucker, or smack their lips",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        They might twist or spread their fingers over and over again, or move them as though they are playing a piano.",
"       </li>",
"       <li>",
"        Their legs might make quick, jerking movements, or slow, writhing movements.",
"       </li>",
"       <li>",
"        Their neck might twist at strange angles, or their hips might thrust.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2368302535\">",
"      <span class=\"h1\">",
"       What causes tardive dyskinesia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Tardive dyskinesia is a side effect of being on certain medicines for a while. Often it starts when the dose of the medicine is lowered, or when the medicine is stopped. The main medicines that cause it include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Medicines called antipsychotics, such as:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?36/63/37877?source=see_link\">",
"         Haloperidol",
"        </a>",
"        (brand name: Haldol&reg;)",
"       </li>",
"       <li>",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?26/6/26725?source=see_link\">",
"         Fluphenazine",
"        </a>",
"       </li>",
"       <li>",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?21/27/21942?source=see_link\">",
"         Risperidone",
"        </a>",
"        (brand name: RisperDAL&reg;)",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?33/45/34517?source=see_link\">",
"         Metoclopramide",
"        </a>",
"        (brand name: Reglan&reg;), which is used to control nausea and vomiting and to treat acid reflux. No one should take this medicine for longer than 3 months. There are other medicines that can be used in its place.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2368302550\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Probably not. If you have been on an antipsychotic medicine for at least a month and you show signs of tardive dyskinesia, the doctor or nurse will probably be able to tell what&rsquo;s wrong. Still, it&rsquo;s possible the doctor or nurse will order blood tests or brain scans to make sure your symptoms are not caused by another problem.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2368302565\">",
"      <span class=\"h1\">",
"       How is tardive dyskinesia treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The treatment usually involves switching antipsychotic medicines or changing the dose. In some cases, the condition will go away or improve a little if the medicine that caused it is stopped. Unfortunately, it is not always possible to stop the medicine.",
"     </p>",
"     <p>",
"      There are also medicines that can be given along with antipsychotic medicines that seem to help with tardive dyskinesia. For example, medicines called benzodiazepines can ease tardive dyskinesia symptoms in people who also have anxiety. If your doctor is not able to control your tardive dyskinesia by switching your antipsychotic medicine or changing your dose, he or she might suggest adding other medicines.",
"     </p>",
"     <p>",
"      People who have abnormal movement only in certain body parts (such as the eyelids) can get injections of a medicine called botulinum toxin. Botulinum toxin, also called BoTox&reg;, can help muscles relax and stop moving abnormally.",
"     </p>",
"     <p>",
"      People with severe tardive dyskinesia that does not improve with other treatment options can sometimes get a treatment called &ldquo;deep brain stimulation&rdquo; (also called &ldquo;DBS&rdquo;). People who get DBS must first have surgery to place wires into a part of the brain that helps control muscle movement. The wires are attached to a device that gets implanted under the skin, usually near the collarbone. It sends electrical signals to the brain to reduce abnormal movement.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2368302580\">",
"      <span class=\"h1\">",
"       Can tardive dyskinesia be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes and no. Tardive dyskinesia is an unfortunate side effect of medicines that people need to take to be well. Most people who take these medications do not get tardive dyskinesia, but some do. It&rsquo;s not always possible to avoid these medicines, so it&rsquo;s not always possible to avoid tardive dyskinesia. Still, there are certain things you can do to reduce the chances of getting the disorder or having a severe form of it. If you are on an antipsychotic medicine, watch out for abnormal movements and let your doctor know right away if you notice any. The earlier the symptoms of tardive dyskinesia are found, the more likely it is that something can be done to prevent the condition from becoming permanent.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2368302595\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/30/483?source=see_link\">",
"       Patient information: Dealing with side effects from medicines (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?31/34/32290?source=see_link\">",
"       Patient information: Taking medicines when you're older (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?1/10/1186?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83900 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-83.177.194.223-B60670ABF6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_10_1186=[""].join("\n");
var outline_f1_10_1186=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2368302505\">",
"      What is tardive dyskinesia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2368302520\">",
"      What are the symptoms of tardive dyskinesia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2368302535\">",
"      What causes tardive dyskinesia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2368302550\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2368302565\">",
"      How is tardive dyskinesia treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2368302580\">",
"      Can tardive dyskinesia be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2368302595\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/30/483?source=related_link\">",
"      Patient information: Dealing with side effects from medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?31/34/32290?source=related_link\">",
"      Patient information: Taking medicines when you're older (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_10_1187="Dentin";
var content_f1_10_1187=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F68204&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F68204&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Scanning electron micrograph of human dentin",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 270px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This scanning electron micrograph shows the odontoblastic processes entering the dentinal tubules in normal human dentin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Wright JT. Normal formation and development defects of the human dentition. Pediatr Clin North Am 2000; 47:975. Copyright &copy; WB Saunders, 2000.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_10_1187=[""].join("\n");
var outline_f1_10_1187=null;
var title_f1_10_1188="Crohns vulva";
var content_f1_10_1188=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F61865&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F61865&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Vulvar involvement in Crohn's disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 349px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from&nbsp;Lynne J Margesson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_10_1188=[""].join("\n");
var outline_f1_10_1188=null;
var title_f1_10_1189="Lamellar ichthyosis";
var content_f1_10_1189=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F59842&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F59842&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lamellar ichthyosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 297px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lamellar ichthyosis: abdomen, child.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Stedman's Medical Dictionary. Copyright &copy;2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_10_1189=[""].join("\n");
var outline_f1_10_1189=null;
var title_f1_10_1190="Fluorouracil (systemic): Pediatric drug information";
var content_f1_10_1190=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Fluorouracil (systemic): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?10/42/10921?source=see_link\">",
"    see \"Fluorouracil (systemic): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?11/24/11653?source=see_link\">",
"    see \"Fluorouracil (systemic): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F8100784\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8100806\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Adrucil&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F10493258\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antineoplastic Agent, Antimetabolite",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F10493685\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?10/42/10921?source=see_link\">",
"      see \"Fluorouracil (systemic): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     Children and Adults (refer to individual protocols with dose based on lean body weight):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Initial: 400-500 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day (12 mg/kg/day; maximum dose: 800 mg/day) for 4-5 days every 4 weeks;",
"     <b>",
"      or",
"     </b>",
"     500-600 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose every 3-4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Maintenance: 200-250 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose (6 mg/kg) every other day for 4 doses; repeat in 4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Single weekly bolus dose of 15 mg/kg or 500 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     can be administered depending on the patient's reaction to the previous course of treatment; maintenance dose of 5-15 mg/kg/week as a single dose not to exceed 1 g/week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V. infusion: 15 mg/kg/day or 500 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day (maximum daily dose: 1 g) has been given by I.V. infusion over 4 hours for 5 days;",
"     <b>",
"      or",
"     </b>",
"     800-1200 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     for continuous infusion over 24-120 hours;",
"     <b>",
"      or",
"     </b>",
"     1000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 3 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"     Bilirubin &gt;5 mg/dL: Not recommended for use",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8100923\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: 50 mg/mL (10 mL, 20 mL, 50 mL, 100 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adrucil&reg;: 50 mg/mL (10 mL, 50 mL, 100 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8100809\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10493686\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Parenteral: Administer by direct I.V. injection (50 mg/mL solution needs no further dilution) over several minutes or by I.V. intermittent or continuous infusion diluted in saline or dextrose solutions; toxicity (eg, myelosuppression) may be reduced by giving the drug as a continuous infusion. Doses &gt;750-800 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     should be administered as a continuous infusion,",
"     <b>",
"      not",
"     </b>",
"     by bolus injection; dose-limiting toxicity with continuous infusion is mucous membrane toxicity (ie, stomatitis, diarrhea)",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F8100860\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Allopurinol, amifostine, anidulafungin, aztreonam, bleomycin, cefepime, cisplatin, cyclophosphamide, doripenem, doxorubicin, doxorubicin liposome, etoposide phosphate, fludarabine, furosemide, gemcitabine, granisetron, heparin, hydrocortisone sodium succinate, leucovorin calcium, linezolid, mannitol, melphalan, methotrexate, metoclopramide, mitomycin, paclitaxel, palonosetron, pemetrexed, piperacillin/tazobactam, potassium chloride, propofol, sargramostim, teniposide, thiotepa, vinblastine, vincristine, vitamin B complex with C.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Aldesleukin, amphotericin B cholesteryl sulfate complex, droperidol, filgrastim, topotecan, vinorelbine.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Gallium nitrate, ondansetron.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F10493496\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at room temperature 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); protect from light; slight discoloration of injection during storage does not affect potency; if precipitate forms, redissolve drug by heating to 140&deg;F, shake well; allow to cool to body temperature before administration; incompatible with ciprofloxacin, cytarabine, diazepam, droperidol, filgrastim, ondansetron, vinorelbine",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10493260\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of carcinoma of stomach, colon, rectum, breast, and pancreas (FDA approved in adults); has also been used for the treatment of head and neck cancer, bladder cancer, hepatoblastoma, and cervical cancer",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8100786\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Fluorouracil may be confused with flucytosine",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F8100836\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Toxicity depends on duration of treatment and/or rate of administration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Angina, arrhythmia, heart failure, MI, myocardial ischemia, vasospasm, ventricular ectopy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Acute cerebellar syndrome, confusion, disorientation, euphoria, headache, nystagmus, stroke",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia, dermatitis, dry skin, fissuring, nail changes (nail loss), palmar-plantar erythrodysesthesia syndrome, pruritic maculopapular rash, photosensitivity, Stevens-Johnson syndrome, toxic epidermal necrolysis, vein pigmentation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, bleeding, diarrhea, esophagopharyngitis, mesenteric ischemia (acute), nausea, sloughing, stomatitis, ulceration, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, anemia, leukopenia (nadir: days 9-14; recovery by day 30), pancytopenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Thrombophlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Lacrimation, lacrimal duct stenosis, photophobia, visual changes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Epistaxis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis, generalized allergic reactions",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10493261\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to fluorouracil or any component; patients with poor nutritional status, bone marrow suppression, or serious infections",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F10493348\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution and modify dosage in patients with renal or hepatic impairment; use with caution in patients who have had high-dose pelvic radiation; palmar-plantar erythrodysesthesia (hand-foot) syndrome has been associated with use. Should be administered under the supervision of a physician experienced in cancer chemotherapy. Due to risk of severe toxic reactions, patients should be hospitalized during the initial course of therapy",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10493263\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA currently recommends that procedures for proper handling and disposal of antineoplastic agents be considered; if intractable vomiting, diarrhea, stomatitis, GI ulceration/bleeding, hemorrhage, or precipitous falls in leukocyte or platelet counts occur, discontinue fluorouracil immediately.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Administration to patients with genetic dihydropyrimidine dehydrogenase (DPD) enzyme deficiency has been associated with increased toxicity following administration (diarrhea, stomatitis, neutropenia, and neurotoxicity). Absence of the DPD enzyme may result in prolonged fluorouracil clearance. Discontinue if symptoms of DPD enzyme deficiency occur.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F9844112\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C9 (strong)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8100851\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carvedilol: CYP2C9 Inhibitors (Strong) may increase the serum concentration of Carvedilol. Specifically, concentrations of the S-carvedilol enantiomer may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Substrates: CYP2C9 Inhibitors (Strong) may decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diclofenac (Systemic): CYP2C9 Inhibitors (Strong) may increase the serum concentration of Diclofenac (Systemic).  Management: Consider using a lower dose of diclofenac when used together with a strong CYP2C9 inhibitor.  Arthrotec (diclofenac and misoprostol) labeling specifically recommends limiting the total daily dose to a maximum of 50 mg twice/day.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Fluorouracil (Systemic) may increase the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gemcitabine: May increase the serum concentration of Fluorouracil (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leucovorin Calcium-Levoleucovorin: May enhance the adverse/toxic effect of Fluorouracil (Systemic). This effect is associated with the ability of leucovorin or levoleucovorin to enhance the anticancer effects of fluorouracil.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MetroNIDAZOLE (Systemic): May increase the serum concentration of Fluorouracil (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ospemifene: CYP2C9 Inhibitors (Strong) may increase the serum concentration of Ospemifene.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Fluorouracil (Systemic) may increase the serum concentration of Phenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: May decrease the serum concentration of Fluorouracil (Systemic). SORAfenib may increase the serum concentration of Fluorouracil (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Fluorouracil (Systemic) may increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Antineoplastic Agents may enhance the anticoagulant effect of Vitamin K Antagonists. Antineoplastic Agents may diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F10493495\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Increase dietary intake of thiamine",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8100827\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8100828\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse effects (increased resorptions, embryolethality, and teratogenicity) have been observed in animal reproduction studies. Based on the mechanism of action, fluorouracil may cause fetal harm if administered during pregnancy (according to the manufacturer&rsquo;s labeling). The National Comprehensive Cancer Network (NCCN) breast cancer guidelines (v.3.2012) state that chemotherapy, if indicated, may be administered to pregnant women with breast cancer as part of a combination chemotherapy regimen (common regimens administered during pregnancy include  doxorubicin, cyclophosphamide, and fluorouracil); chemotherapy should not be administered during the first trimester, after 35 weeks gestation, or within 3 weeks of planned delivery.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F10493687\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential and platelet count, renal function tests, liver function tests; observe for changes in bowel frequency",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10493619\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A pyrimidine antimetabolite that inhibits thymidylate synthase leading to depletion of the DNA precursor thymidine; incorporated into RNA, DNA",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F10493620\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: Into tumors, intestinal mucosa, liver, bone marrow, ascitic fluid, brain tissue, and CSF",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: &lt;10%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Inactive metabolites are formed following metabolism in the liver",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: 50% to 80%; variable due to saturable first-pass elimination process",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life, biphasic:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Alpha: 10-20 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Terminal: 15-19 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elimination: Biphasic elimination with &lt;10% of dose excreted unchanged in the urine; 25% to 80% excreted as respiratory CO",
"     <sub>",
"      2",
"     </sub>",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F10493688\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?11/24/11653?source=see_link\">",
"      see \"Fluorouracil (systemic): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid alcohol; maintain adequate hydration; report signs and symptoms of infection, bleeding, bruising, vision changes, unremitting nausea, vomiting, or diarrhea, chest pain or palpitations, or CNS changes. May cause photosensitivity reactions (eg, exposure to sunlight may cause severe sunburn, skin rash, redness, or itching); avoid exposure to sunlight and artificial light sources (sunlamps, tanning booth/bed); wear protective clothing, wide-brimmed hats, sunglasses, and lip sunscreen (SPF &ge;15); use a sunscreen [broad-spectrum sunscreen or physical sunscreen (preferred) or sunblock with SPF &ge;15]; contact physician if reaction occurs. Women of childbearing age should be advised to avoid becoming pregnant.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F10493690\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Myelosuppressive effects:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     WBC: Mild",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Platelets: Mild",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset (days): 7-10",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nadir (days): 9-14",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Recovery (days): 21",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Balis FM, Holcenberg JS and Bleyer WA, &ldquo;Clinical Pharmacokinetics of Commonly Used Anticancer Drugs,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1983, 8(3):202-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/10/1190/abstract-text/6189661 /pubmed\" id=\"6189661 \" target=\"_blank\">",
"        6189661",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ortega JA, Douglass EC, Feusner JH, et al, \"Randomized Comparison of Cisplatin/Vincristine/Fluorouracil and Cisplatin/Continuous Infusion Doxorubicin for Treatment of Pediatric Hepatoblastoma: A Report From the Children's Cancer Group and the Pediatric Oncology Group,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2000, 18(14):2665-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/10/1190/abstract-text/10894865/pubmed\" id=\"10894865\" target=\"_blank\">",
"        10894865",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rodriguez-Galindo C, Wofford M, Castleberry RP, et al, \"Preradiation Chemotherapy With Methotrexate, Cisplatin, 5-Fluorouracil, and Leucovorin for Pediatric Nasopharyngeal Carcinoma,\"",
"      <i>",
"       Cancer",
"      </i>",
"      , 2005, 103(4):850-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/10/1190/abstract-text/15641027/pubmed\" id=\"15641027\" target=\"_blank\">",
"        15641027",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15990 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-CDD449C725-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_10_1190=[""].join("\n");
var outline_f1_10_1190=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8100784\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8100806\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10493258\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10493685\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8100923\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8100809\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10493686\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8100860\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10493496\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10493260\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8100786\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8100836\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10493261\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10493348\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10493263\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9844112\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8100851\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10493495\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8100827\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8100828\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10493687\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10493619\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10493620\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10493688\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10493690\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15990\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15990|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?10/42/10921?source=related_link\">",
"      Fluorouracil (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?11/24/11653?source=related_link\">",
"      Fluorouracil (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?12/58/13221?source=related_link\">",
"      Fluorouracil (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?40/27/41396?source=related_link\">",
"      Fluorouracil (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/52/29508?source=related_link\">",
"      Fluorouracil (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_10_1191="Opioid detoxification during treatment for addiction";
var content_f1_10_1191=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Opioid detoxification during treatment for addiction",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/10/1191/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/10/1191/contributors\">",
"     Michael F Weaver, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/10/1191/contributors\">",
"     John A Hopper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/10/1191/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/10/1191/contributors\">",
"     Andrew J Saxon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/10/1191/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/10/1191/contributors\">",
"     Richard Hermann, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/10/1191/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 13, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Humans have used opiates (substances derived from opium) for pain relief and pleasure for millennia. Opioids include both natural and synthetic agents (eg, heroin) with properties similar to opium. In recent decades, opioid abuse and withdrawal have become a major international public health problem. As the availability and purity of heroin and other opioids has increased, so has the number of opioid overdoses and overdose deaths [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1191/abstract/1\">",
"     1",
"    </a>",
"    ]. State and local authorities that report abuse and diversion of controlled substance prescriptions, especially opioid analgesics, as the primary drug threat has doubled from 5 to 10 percent in the past five years [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1191/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnosis and management of opioid withdrawal will be reviewed here, focusing on management in the course of treatment for drug addiction. The management of unplanned withdrawal in the emergency department and issues related to chronic opioid abuse and opioid intoxication are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/5/28758?source=see_link\">",
"     \"Opioid withdrawal in the emergency setting\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/52/29514?source=see_link\">",
"     \"Treatment of opioid abuse and dependence\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/51/3897?source=see_link\">",
"     \"Opioid intoxication in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OPIOID WITHDRAWAL",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Symptoms of opiate withdrawal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tolerance and physical and psychologic dependence on opioids usually occur after three weeks of daily usage. Higher tolerance is created as the user decreases the interval and increases the dose to achieve euphoria. Tolerance does not develop to the miotic effects or constipation.",
"   </p>",
"   <p>",
"    Although all opioids can cause addiction, heroin has the greatest addictive potential (reinforcement). Heroin provides a \"rush\" because it easily crosses the blood brain barrier leading to rapidly elevated central nervous system (CNS) levels.",
"   </p>",
"   <p>",
"    The discontinuation of opioids leads to a constellation of withdrawal symptoms known as the abstinence syndrome (",
"    <a class=\"graphic graphic_table graphicRef78321 \" href=\"UTD.htm?3/26/3499\">",
"     table 1",
"    </a>",
"    ). The severity of its symptoms depends upon the type and frequency of the drug used. The withdrawal syndrome usually occurs if opioid use is discontinued after several weeks of steady use. Withdrawal symptoms following abrupt discontinuation of heroin have approximately twice the severity, but a shorter duration, compared to equivalent doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     buprenorphine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Withdrawal symptoms occur in stages, depending upon the time of the last dose and the half-life of the opioid used. For a short-acting opioid, such as heroin, the typical withdrawal course is [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1191/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Three to four hours after last dose &mdash; Drug craving, anxiety, fear of withdrawal",
"     </li>",
"     <li>",
"      8 to 14 hours after last dose &mdash; Anxiety, restlessness, insomnia, yawning, rhinorrhea, lacrimation, diaphoresis, stomach cramps, and mydriasis",
"     </li>",
"     <li>",
"      One to three days after last dose &mdash; Tremor, muscle spasms, vomiting, diarrhea, tachycardia, chills, and piloerection",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The time course of withdrawal symptom severity depends upon the half-life of the drug involved. Withdrawal symptoms from heroin reach a peak approximately three to four days after abrupt discontinuation of the drug. Withdrawal from equivalent doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     buprenorphine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    reach a peak severity at approximately four and eight days, respectively, after discontinuation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1191/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Management of acute withdrawal",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, abrupt discontinuation of opioids is not recommended because of the extreme anxiety and discomfort experienced by opioid users upon sudden drug cessation.",
"   </p>",
"   <p>",
"    Temporary substitution with a long-acting opioid reduces withdrawal severity [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1191/abstract/3\">",
"     3",
"    </a>",
"    ]. Several different types of facilities are appropriate for management of opioid withdrawal. This is often done as outpatient detoxification using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    in a licensed opioid treatment program or with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     buprenorphine",
"    </a>",
"    as office-based opioid treatment. Opioid withdrawal also can be managed in a hospital setting if the patient is admitted for a diagnosis other than opioid addiction, but hospitalization is usually unnecessary unless the patient has concurrent medical or psychologic problems [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1191/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Virtually any opioid can be administered to relieve acute withdrawal symptoms (",
"    <a class=\"graphic graphic_table graphicRef58864 \" href=\"UTD.htm?11/31/11760\">",
"     table 2",
"    </a>",
"    ). The effects of short-acting medications can be controlled precisely but require frequent assessment and dose adjustment, and patients may experience severe withdrawal symptoms toward the end of the dosing period. Short-acting medications are most appropriately used in intensive care units or in other situations when the patient's condition is likely to change rapidly and the patient can be closely monitored. Long-acting medications are more convenient for medical and nursing staff and produce less severe withdrawal symptoms themselves (if any symptoms are seen), but the withdrawal symptoms may last for long periods of time. Long-acting medications are most appropriately used when the patient is medically stable, aside from opiate withdrawal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Methadone",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     Methadone",
"    </a>",
"    is frequently used to treat acute withdrawal symptoms from opioids. Current US Federal regulations restrict the use of methadone for treatment of opioid addiction. Methadone may be used by a private practice physician for temporary maintenance or detoxification when an addicted patient is admitted to a hospital for an illness other than opioid addiction. It may also be used by a private practitioner in an outpatient setting when administered daily for a maximum of three days, while a patient awaits admission into a licensed methadone treatment program.",
"   </p>",
"   <p>",
"    There is no clear evidence that the severity of withdrawal symptoms is related to the amount of opioid being used. Nevertheless, a method of titrating the amount of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    based upon symptoms has been used extensively to titrate methadone for opioid withdrawal, without causing over-sedation or severe patient discomfort. The severity of 11 symptoms (",
"    <a class=\"graphic graphic_form graphicRef53521 \" href=\"UTD.htm?12/60/13262\">",
"     form 1",
"    </a>",
"    ) are each graded on a score of 0 to 2 points. Zero points are assigned if the symptom is absent, 1 point if the symptom is present, and 2 points if the symptom is severe. The total score for all symptoms is determined; each point is equivalent to a requirement of 1 mg of methadone, although there is no need to give any methadone for a score of less than 5 points, since such a low score indicates only mild withdrawal. The patient should be evaluated and the symptom score totaled every six hours for the first 24 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1191/abstract/5\">",
"     5",
"    </a>",
"    ]. This process can also be followed when using opiates other than methadone to manage acute withdrawal, with more frequent assessments for shorter-acting opioids.",
"   </p>",
"   <p>",
"    After 24 hours, the total dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    that has been administered is computed; this dose is approximately equivalent to the dose of opioid the individual was taking. After being stabilized on this dose of methadone, the patient can be medically withdrawn by gradually reducing the dose. The total daily intake should be reduced by approximately 10 percent per day. The duration of action of methadone allows it to be given once daily as a single dose when treating opioid withdrawal, in contrast to pain management. Patients do not experience a \"rush\" with methadone administration.",
"   </p>",
"   <p>",
"    Frequently patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    require analgesic medications for coexisting medical problems. Attempts should be made to control the pain through the use of nonopioid analgesics in most cases. If this is not possible, the dose of methadone that the patient is receiving should be used as a baseline, with additional opioid analgesics added in standard therapeutic doses to control the pain.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/48/29446?source=see_link\">",
"     Pentazocine",
"    </a>",
"    (Talwin),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/45/14038?source=see_link\">",
"     nalbuphine",
"    </a>",
"    (Nubain), and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9543?source=see_link\">",
"     butorphanol",
"    </a>",
"    (Stadol) should",
"    <strong>",
"     not",
"    </strong>",
"    be administered to any patient taking pure agonists such as methadone because these drugs have antagonist properties and can precipitate an immediate withdrawal syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Buprenorphine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     Buprenorphine",
"    </a>",
"    is a partial opioid agonist (in contrast to a pure opioid agonist like",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    ) and so may cause fewer withdrawal symptoms and have less potential for respiratory depression in overdose [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1191/abstract/6\">",
"     6",
"    </a>",
"    ]. Buprenorphine dissociates very slowly from opioid receptors, so it has a long duration of action.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     Buprenorphine",
"    </a>",
"    is taken sublingually. It is available alone (brand name Subutex) or in a combination preparation (brand name Suboxone) with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"     naloxone",
"    </a>",
"    , an opioid antagonist that has poor oral absorption. The rationale for combination therapy is that naloxone will have little to no activity when administered sublingually, but it should discourage intravenous buprenorphine abuse since it may precipitate withdrawal if used parenterally by opioid dependent individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1191/abstract/7\">",
"     7",
"    </a>",
"    ].",
"    <span class=\"nowrap\">",
"     Buprenorphine/naloxone",
"    </span>",
"    is used more often than buprenorphine alone for induction and detoxification or maintenance treatment. Both daily and alternate-day dosing have equivalent effects on opioid withdrawal symptoms and heroin use [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1191/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the United States, the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     buprenorphine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/51/24375?source=see_link\">",
"     buprenorphine-naloxone",
"    </a>",
"    for the treatment of opioid addiction is restricted to qualified physicians who have received training and received a waiver to practice medication- assisted opioid addiction therapy with Schedule III, IV, or V narcotic medications specifically approved by the US Food and Drug Administration (FDA) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1191/abstract/9\">",
"     9",
"    </a>",
"    ]. Information about training opportunities is available at the Substance Abuse and Mental Health Services Administration website (",
"    <a class=\"external\" href=\"file://buprenorphine.samhsa.gov/pls/bwns/training\">",
"     file://buprenorphine.samhsa.gov/pls/bwns/training",
"    </a>",
"    ). There is a national network of physicians experienced in addiction treatment with buprenorphine and skilled in clinical education who are available to assist practicing physicians in incorporating buprenorphine treatment into a practice (this information is available at",
"    <a class=\"external\" href=\"file://buprenorphine.samhsa.gov/\">",
"     buprenorphine.samhsa.gov",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     Buprenorphine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/51/24375?source=see_link\">",
"     buprenorphine-naloxone",
"    </a>",
"    have been used for detoxification with protocols that have ranged from one day of buprenorphine dosing to as long as seven weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1191/abstract/10-13\">",
"     10-13",
"    </a>",
"    ]. Success rates with these schedules are comparable to similar tapering schedules for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    , although longer courses with more gradual tapering appear to be superior to rapid tapering [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1191/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     Buprenorphine",
"    </a>",
"    induction, like",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    , can be performed to accomplish acute withdrawal treatment or to transition to maintenance buprenorphine treatment. Maintenance should be considered for patients with chronic relapsing opioid dependence [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1191/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients should abstain from shorter-acting opioids (eg, heroin or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/34/10792?source=see_link\">",
"     oxycodone",
"    </a>",
"    ) for 12 to 24 hours, and from longer acting opioids (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    , sustained-release oxycodone, sustained-release",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    ) for 24 to 36 hours before initiating",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     buprenorphine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/51/24375?source=see_link\">",
"     buprenorphine-naloxone",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1191/abstract/15\">",
"     15",
"    </a>",
"    ]. Buprenorphine has a high affinity for the mu receptor but is only partially active. If buprenorphine is initiated prior to the onset of acute withdrawal signs and symptoms, patients who are physically dependent on opioids may experience an abrupt withdrawal syndrome (\"precipitated withdrawal\") resulting from displacement of full agonists of the mu-opioid receptor by the partial agonist buprenorphine.",
"   </p>",
"   <p>",
"    Patients are usually induced with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/51/24375?source=see_link\">",
"     buprenorphine-naloxone",
"    </a>",
"    by administering the drug with gradual dose increments over 24 hours. Typical day one doses are 8 to 16 mg. Over the next two to five days, stabilization doses will range from 8 to 32 mg daily, although there is significant variability in individual dose response [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1191/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Typical maintenance doses will range from 8 to 24 mg per day.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Clonidine and other drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     Clonidine",
"    </a>",
"    , an alpha-2 adrenergic receptor agonist, reduces catecholamine release in the sympathetic nervous system and may decrease withdrawal symptoms in patients taking low doses of opioids [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1191/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. Clonidine also can be used to facilitate",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    withdrawal when the methadone dose is tapered below 15 mg [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1191/abstract/21\">",
"     21",
"    </a>",
"    ]. In addition, clonidine has been used in conjunction with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"     naloxone",
"    </a>",
"    as part of a protocol for rapid opioid detoxification to help ameliorate the severity of symptoms from naloxone-induced opioid withdrawal [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1191/abstract/22\">",
"     22",
"    </a>",
"    ]. Clonidine is not approved by the US FDA for the treatment of opioid withdrawal, although it is commonly used for this purpose.",
"   </p>",
"   <p>",
"    It is important to monitor for hypotension during",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    therapy and then to taper clonidine gradually to avoid a hypertensive rebound [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1191/abstract/23\">",
"     23",
"    </a>",
"    ]. A transdermal clonidine patch is effective for mild withdrawal symptoms and can be left on the skin for seven days.",
"   </p>",
"   <p>",
"    Typical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    protocols use 0.1 to 0.3 mg of clonidine every two to four hours for the first 24 hours. Total doses given in day one and two will usually be in the range of 0.8 to 1.2 mg per day. Subsequently, clonidine is usually given three to four times a day, with the total daily dose reduced by 0.1 or 0.2 mg on each subsequent day. The total duration of therapy for this regimen is between 10 and 14 days.",
"   </p>",
"   <p>",
"    In addition to orthostatic hypotension, side effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    include sedation, dry mouth, and constipation. These side effects are more likely at higher clonidine doses.",
"   </p>",
"   <p>",
"    Some patients appear to get a euphoric effect with the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    , and instances of patients ingesting clonidine for abuse have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1191/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lofexidine, another alpha-2 adrenergic agonist, is an analogue of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    with a lower incidence of side effects, particularly hypotension [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1191/abstract/23\">",
"     23",
"    </a>",
"    ]. Detoxification from heroin using a combination of lofexidine and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"     naloxone",
"    </a>",
"    demonstrated improved treatment retention and longer time to relapse than lofexidine alone, or a rapid (ten day)",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    taper [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1191/abstract/26\">",
"     26",
"    </a>",
"    ]. Lofexidine has been used in the United Kingdom for opioid detoxification for over ten years, but is not currently FDA-approved in the US. Phase II clinical trials are ongoing under the direction of the US National Institute on Drug Abuse (NIDA).",
"   </p>",
"   <p>",
"    Additional medications may be given for relief of other acute symptoms of opioid withdrawal: muscle relaxants reduce spasms and twitching; nonsteroidal antiinflammatory drugs (NSAIDs) treat aches; antiemetics are used for nausea; an antidiarrheal agent such as bismuth subsalicylate may be useful; and a sleeping medication that has low abuse potential (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/0/24584?source=see_link\">",
"     trazodone",
"    </a>",
"    ) will help insomnia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Rapid and ultrarapid opioid detoxification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rapid opioid detoxification techniques have been developed in an effort to get patients through the detoxification process quickly and on to the maintenance phase of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1191/abstract/27-30\">",
"     27-30",
"    </a>",
"    ]. Rapid detoxification has been studied using a variety of protocols, usually including opioid antagonists such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"     naloxone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/16/39173?source=see_link\">",
"     naltrexone",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    , with or without adjunctive medications such as benzodiazepines, antiemetics, and NSAIDs.",
"   </p>",
"   <p>",
"    A method of ultrashort opioid detoxification also has been developed in which the substance-abusing patient undergoes opioid antagonist-induced withdrawal while under general anesthesia [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1191/abstract/12,31\">",
"     12,31",
"    </a>",
"    ]. Patients are anesthetized, then intubated and mechanically ventilated. They are given a large bolus of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"     naloxone",
"    </a>",
"    to precipitate acute opioid withdrawal while unconscious and a diuretic to enhance excretion of the opioid. Patients experience mild withdrawal symptoms for about six days after awakening from anesthesia, compared with similar withdrawal symptoms on a 20-day",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    taper.",
"   </p>",
"   <p>",
"    Serious complications have been reported with anesthesia-assisted rapid detoxification [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1191/abstract/32\">",
"     32",
"    </a>",
"    ], and a randomized trial did not find it to be superior to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     buprenorphine",
"    </a>",
"    -assisted rapid detoxification, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    -assisted detoxification [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1191/abstract/12\">",
"     12",
"    </a>",
"    ]. In this study, the three detoxification strategies resulted in no differences in rates of completion of inpatient detoxification or completion of the treatment program at 12 weeks; the overall dropout rate was 82 percent. There were three serious adverse events, all occurring in the anesthesia group. A systematic review of five randomized trials found that the potential serious harms and costs of heavy sedation or anesthesia, and lack of benefit from this procedure, do not support this method of detoxification [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1191/abstract/33\">",
"     33",
"    </a>",
"    ]. We believe that ultrarapid opiate detoxification is not a medically sound therapy and should be avoided. Guidelines from the UK National Institute for Health and Clinical Excellence (NICE) also recommend against ultrarapid detoxification [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1191/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The discontinuation of opioids leads to a constellation of withdrawal symptoms known as the abstinence syndrome (",
"      <a class=\"graphic graphic_table graphicRef78321 \" href=\"UTD.htm?3/26/3499\">",
"       table 1",
"      </a>",
"      ). The severity of its symptoms depends upon the type and frequency of the drug used. The withdrawal syndrome usually occurs if opioid use is discontinued after several weeks of steady use. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Symptoms of opiate withdrawal'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In acute detoxification,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"       methadone",
"      </a>",
"      can completely alleviate withdrawal symptoms and craving when prescribed in sufficient dosages. Treatments involving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"       buprenorphine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"       clonidine",
"      </a>",
"      are reasonable alternatives. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Opioid withdrawal'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend",
"      <strong>",
"       not",
"      </strong>",
"      using ultrashort opioid detoxification procedures with general anesthesia.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     file://www.justice.gov/ndic/pubs38/38661 (Accessed on May 10, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1191/abstract/2\">",
"      Kosten TR, O'Connor PG. Management of drug and alcohol withdrawal. N Engl J Med 2003; 348:1786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1191/abstract/3\">",
"      Amato L, Davoli M, Ferri M, Ali R. Methadone at tapered doses for the management of opioid withdrawal. Cochrane Database Syst Rev 2002; :CD003409.",
"     </a>",
"    </li>",
"    <li>",
"     Mee-Lee, D, Shulman, G, Gartner, L. ASAM Patient Placement Criteria for the Treatment of Psychoactive Substance-Related Disorders, 2nd ed, Chevy Chase: American Society of Addiction Medicine 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1191/abstract/5\">",
"      Weaver MF, Jarvis MA, Schnoll SH. Role of the primary care physician in problems of substance abuse. Arch Intern Med 1999; 159:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1191/abstract/6\">",
"      Walsh SL, Preston KL, Stitzer ML, et al. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther 1994; 55:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1191/abstract/7\">",
"      Buprenorphine: an alternative to methadone. Med Lett Drugs Ther 2003; 45:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1191/abstract/8\">",
"      Johnson RE, Eissenberg T, Stitzer ML, et al. Buprenorphine treatment of opioid dependence: clinical trial of daily versus alternate-day dosing. Drug Alcohol Depend 1995; 40:27.",
"     </a>",
"    </li>",
"    <li>",
"     file://buprenorphine.samhsa.gov (Accessed May 12, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1191/abstract/10\">",
"      Cheskin LJ, Fudala PJ, Johnson RE. A controlled comparison of buprenorphine and clonidine for acute detoxification from opioids. Drug Alcohol Depend 1994; 36:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1191/abstract/11\">",
"      Bickel WK, Stitzer ML, Bigelow GE, et al. A clinical trial of buprenorphine: comparison with methadone in the detoxification of heroin addicts. Clin Pharmacol Ther 1988; 43:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1191/abstract/12\">",
"      Collins ED, Kleber HD, Whittington RA, Heitler NE. Anesthesia-assisted vs buprenorphine- or clonidine-assisted heroin detoxification and naltrexone induction: a randomized trial. JAMA 2005; 294:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1191/abstract/13\">",
"      O'Connor PG. Methods of detoxification and their role in treating patients with opioid dependence. JAMA 2005; 294:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1191/abstract/14\">",
"      Amass L, Bickel WK, Higgins ST, Hughes JR. A preliminary investigation of outcome following gradual or rapid buprenorphine detoxification. J Addict Dis 1994; 13:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1191/abstract/15\">",
"      Sullivan LE, Fiellin DA. Narrative review: buprenorphine for opioid-dependent patients in office practice. Ann Intern Med 2008; 148:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1191/abstract/16\">",
"      Fudala PJ, Bridge TP, Herbert S, et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med 2003; 349:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1191/abstract/17\">",
"      Greenwald MK, Johanson CE, Moody DE, et al. Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers. Neuropsychopharmacology 2003; 28:2000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1191/abstract/18\">",
"      Gold MS, Pottash AC, Sweeney DR, Kleber HD. Opiate withdrawal using clonidine. A safe, effective, and rapid nonopiate treatment. JAMA 1980; 243:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1191/abstract/19\">",
"      Gold MS, Redmond DE Jr, Kleber HD. Clonidine in opiate withdrawal. Lancet 1978; 1:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1191/abstract/20\">",
"      Kasvikis Y, Bradley B, Gossop M, et al. Clonidine versus long- and short-term methadone-aided withdrawal from opiates. An uncontrolled comparison. Int J Addict 1990; 25:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1191/abstract/21\">",
"      Charney DS, Sternberg DE, Kleber HD, et al. The clinical use of clonidine in abrupt withdrawal from methadone. Effects on blood pressure and specific signs and symptoms. Arch Gen Psychiatry 1981; 38:1273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1191/abstract/22\">",
"      Loimer N, Hofmann P, Chaudhry H. Ultrashort noninvasive opiate detoxification. Am J Psychiatry 1993; 150:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1191/abstract/23\">",
"      Gowing L, Farrell M, Ali R, White J. Alpha2 adrenergic agonists for the management of opioid withdrawal. Cochrane Database Syst Rev 2004; :CD002024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1191/abstract/24\">",
"      Lauzon P. Two cases of clonidine abuse/dependence in methadone-maintained patients. J Subst Abuse Treat 1992; 9:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1191/abstract/25\">",
"      Beuger M, Tommasello A, Schwartz R, Clinton M. Clonidine use and abuse among methadone program applicants and patients. J Subst Abuse Treat 1998; 15:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1191/abstract/26\">",
"      McCambridge J, Gossop M, Beswick T, et al. In-patient detoxification procedures, treatment retention, and post-treatment opiate use: comparison of lofexidine + naloxone, lofexidine + placebo, and methadone. Drug Alcohol Depend 2007; 88:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1191/abstract/27\">",
"      Loimer N, Linzmayer L, Gr&uuml;nberger J. Comparison between observer assessment and self rating of withdrawal distress during opiate detoxification. Drug Alcohol Depend 1991; 28:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1191/abstract/28\">",
"      Loimer N, Linzmayer L, Schmid R, Gr&uuml;nberger J. Similar efficacy of abrupt and gradual opiate detoxification. Am J Drug Alcohol Abuse 1991; 17:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1191/abstract/29\">",
"      Loimer N, Schmid R, Lenz K, et al. Acute blocking of naloxone-precipitated opiate withdrawal symptoms by methohexitone. Br J Psychiatry 1990; 157:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1191/abstract/30\">",
"      O'Connor PG, Kosten TR. Rapid and ultrarapid opioid detoxification techniques. JAMA 1998; 279:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1191/abstract/31\">",
"      Kienbaum P, Scherbaum N, Th&uuml;rauf N, et al. Acute detoxification of opioid-addicted patients with naloxone during propofol or methohexital anesthesia: a comparison of withdrawal symptoms, neuroendocrine, metabolic, and cardiovascular patterns. Crit Care Med 2000; 28:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1191/abstract/32\">",
"      Hamilton RJ, Olmedo RE, Shah S, et al. Complications of ultrarapid opioid detoxification with subcutaneous naltrexone pellets. Acad Emerg Med 2002; 9:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1191/abstract/33\">",
"      Gowing L, Ali R, White J. Opioid antagonists under heavy sedation or anaesthesia for opioid withdrawal. Cochrane Database Syst Rev 2006; :CD002022.",
"     </a>",
"    </li>",
"    <li>",
"     National Institute for Health and Clinical Excellence. Drug misuse: opioid detoxification. London:NICE, 2007. www.nice.org.uk/CG052.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7808 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-180.241.123.62-C1AFB1FE5C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_10_1191=[""].join("\n");
var outline_f1_10_1191=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OPIOID WITHDRAWAL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Symptoms of opiate withdrawal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Management of acute withdrawal",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Methadone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Buprenorphine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Clonidine and other drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Rapid and ultrarapid opioid detoxification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/7808\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/7808|Form\">",
"      <a href=\"#\" title=\"FORMS\">",
"       FORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_form\" href=\"UTD.htm?12/60/13262\" title=\"form 1\">",
"      Methadone dose calculation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/7808|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/26/3499\" title=\"table 1\">",
"      Stages of opiate withdrawal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/31/11760\" title=\"table 2\">",
"      Select opioids chronic pain and equianalgesic doses",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/51/3897?source=related_link\">",
"      Opioid intoxication in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/5/28758?source=related_link\">",
"      Opioid withdrawal in the emergency setting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/52/29514?source=related_link\">",
"      Treatment of opioid abuse and dependence",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_10_1192="Antibodies to double-stranded (ds)DNA, Sm, and U1 RNP";
var content_f1_10_1192=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Antibodies to double-stranded (ds)DNA, Sm, and U1 RNP",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/10/1192/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/10/1192/contributors\">",
"     Donald B Bloch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/10/1192/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/10/1192/contributors\">",
"     Robert H Shmerling, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/10/1192/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/10/1192/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/10/1192/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H157844\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Selected antinuclear antibodies (ANAs), including anti-double-stranded deoxyribonucleic acid (dsDNA) and anti-Sm, are highly specific for the diagnosis of systemic lupus erythematosus (SLE). Antibodies directed against the U1 ribonucleoprotein (RNP) complex are markers for mixed connective tissue disease (MCTD) and may be seen in patients with SLE and other disorders. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/16/3338?source=see_link\">",
"     \"Diagnosis and differential diagnosis of systemic lupus erythematosus in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/23/3447?source=see_link\">",
"     \"Definition and diagnosis of mixed connective tissue disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The sensitivity of anti-dsDNA, anti-Sm, and anti-U1 RNP antibodies for the diagnosis of SLE is relatively low, but the specificity of anti-dsDNA and anti-Sm antibodies for SLE makes them invaluable tools to assist in the diagnosis of this disease.",
"   </p>",
"   <p>",
"    This topic will review the clinical significance of anti-dsDNA, anti-Sm, and anti-U1 RNP autoantibodies. The clinical significance of anti-ribosomal P autoantibodies, which are also highly specific for the diagnosis of SLE, and of other antinuclear antibodies is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27718?source=see_link\">",
"     \"Antiribosomal P protein antibodies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28520?source=see_link\">",
"     \"Measurement and clinical significance of antinuclear antibodies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/44/42695?source=see_link\">",
"     \"Miscellaneous antinuclear antibodies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANTI-DNA ANTIBODIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibodies to DNA can be primarily divided into two groups: those reactive with denatured, single-stranded (ss)DNA and those recognizing native, double-stranded (ds)DNA [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1192/abstract/1\">",
"     1",
"    </a>",
"    ]. Autoantibodies to DNA were first described in the 1950s. Their binding to cell nuclei, using a Hep-2 cell line substrate, for example, may be visualized by indirect immunofluorescent (IIF) staining (",
"    <a class=\"graphic graphic_picture graphicRef74351 \" href=\"UTD.htm?41/32/42499\">",
"     picture 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Anti-ssDNA antibodies'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H4\">",
"     'Anti-dsDNA antibodies'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Anti-ssDNA antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anti-ssDNA antibodies are generally not useful in the diagnosis and management of SLE. Antibodies that identify ssDNA react primarily with the purine and pyrimidine bases that are buried within the beta helix of dsDNA [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1192/abstract/2\">",
"     2",
"    </a>",
"    ]. Because these epitopes are &ldquo;hidden&rdquo; when DNA is in its native configuration, antibodies directed against ssDNA do not usually crossreact with dsDNA. Antibodies to ssDNA have the following general properties:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      They have been eluted from the kidneys of patients with proliferative lupus nephritis and may, therefore, be of pathogenic significance [",
"      <a class=\"abstract\" href=\"UTD.htm?1/10/1192/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      They are much less specific for SLE than antibodies to dsDNA. As an example, anti-ssDNA antibodies have been reported in rheumatoid arthritis, in drug-related lupus, in healthy relatives of patients with SLE [",
"      <a class=\"abstract\" href=\"UTD.htm?1/10/1192/abstract/4\">",
"       4",
"      </a>",
"      ], and, less commonly, in other rheumatic diseases and healthy persons [",
"      <a class=\"abstract\" href=\"UTD.htm?1/10/1192/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Anti-ssDNA antibody testing is not useful for the management of patients with SLE because the presence and titer of anti-ssDNA antibodies do not correlate well with SLE disease activity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Anti-dsDNA antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anti-dsDNA antibodies are useful in the evaluation and management of patients with SLE because of their high specificity and association, in some patients, with disease activity. They have received a significant amount of attention for several reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anti-dsDNA antibodies are specific for SLE, making the presence of these antibodies very useful for distinguishing patients with SLE from patients with other systemic autoimmune diseases [",
"      <a class=\"abstract\" href=\"UTD.htm?1/10/1192/abstract/5\">",
"       5",
"      </a>",
"      ]. Anti-dsDNA antibodies are rarely found in patients with other disorders, including rheumatoid arthritis, Sj&ouml;gren&rsquo;s syndrome, scleroderma, Raynaud phenomenon, mixed connective tissue disease, discoid lupus, myositis, uveitis, juvenile arthritis, antiphospholipid syndrome, Grave&rsquo;s disease, Alzheimer disease, and autoimmune hepatitis [",
"      <a class=\"abstract\" href=\"UTD.htm?1/10/1192/abstract/5,6\">",
"       5,6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Titers of anti-dsDNA antibodies often fluctuate with SLE disease activity. When anti-dsDNA antibody levels are integrated with other measures of disease activity, they are useful in the clinical management of SLE patients [",
"      <a class=\"abstract\" href=\"UTD.htm?1/10/1192/abstract/5,7-9\">",
"       5,7-9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There is a well-recognized association between the presence of high titer immunoglobulin G (IgG) anti-dsDNA antibodies and active glomerulonephritis [",
"      <a class=\"abstract\" href=\"UTD.htm?1/10/1192/abstract/2,8-14\">",
"       2,8-14",
"      </a>",
"      ]. There is also evidence of deposition of dsDNA-containing immune complexes in the glomeruli of patients with active lupus nephritis. These observations have led investigators to believe that anti-dsDNA antibodies are of primary importance in the pathogenesis of lupus nephritis [",
"      <a class=\"abstract\" href=\"UTD.htm?1/10/1192/abstract/9,15\">",
"       9,15",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/3/27706?source=see_link\">",
"       \"Diagnosis and classification of renal disease in systemic lupus erythematosus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Although patients with drug-induced lupus typically develop antibodies directed against ssDNA and histone proteins, anti-dsDNA antibodies have been reported in patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"       minocycline",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"       penicillamine",
"      </a>",
"      . Along with the production of anti-dsDNA antibodies, these patients may develop a syndrome of arthritis, arthralgias, cutaneous vasculitis, and serositis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/32/28168?source=see_link\">",
"       \"Drug-induced lupus\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Measurement of anti-dsDNA",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are four principal methods used to detect and quantify anti-dsDNA antibodies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Farr assay",
"      </strong>",
"      &mdash; The Farr assay is based upon the precipitation of radioactively labeled DNA-anti-DNA antibody complexes in a 50 percent saturated ammonium sulfate solution. This assay primarily detects high affinity antibodies to dsDNA [",
"      <a class=\"abstract\" href=\"UTD.htm?1/10/1192/abstract/16\">",
"       16",
"      </a>",
"      ]. Approximately 50 to 80 percent of all SLE patients have elevated levels of anti-dsDNA antibodies measured by this method; the antibody level appears to correlate closely with disease activity, especially with active proliferative nephritis [",
"      <a class=\"abstract\" href=\"UTD.htm?1/10/1192/abstract/2,16\">",
"       2,16",
"      </a>",
"      ]. The Farr assay is no longer widely used for the detection of anti-dsDNA antibodies because it requires the use of a radioactive DNA as target antigen and because of the expense associated with disposal of radioactive material.",
"     </li>",
"     <li>",
"      <strong>",
"       Crithidia luciliae assay",
"      </strong>",
"      &mdash; The Crithidia luciliae assay is an IIF assay that takes advantage of the fact that the basal body of this unicellular hemoflagellate contains a kinetoplast or a giant mitochondrion. The mitochondrion contains a small circle of DNA that consists exclusively of dsDNA [",
"      <a class=\"abstract\" href=\"UTD.htm?1/10/1192/abstract/17\">",
"       17",
"      </a>",
"      ]. As in the IIF test for ANAs using the HEp-2 cells substrate, a semiquantitative measure of anti-dsDNA antibodies is determined by testing serial dilutions of serum on the hemoflagellate substrate [",
"      <a class=\"abstract\" href=\"UTD.htm?1/10/1192/abstract/18,19\">",
"       18,19",
"      </a>",
"      ]. The highest titer of serum that stains the kinetoplast is considered the titer of anti-dsDNA antibody in the patient serum. The Crithidia luciliae assay is of comparable sensitivity to the Farr assay.",
"     </li>",
"     <li>",
"      <strong>",
"       ELISA",
"      </strong>",
"      &mdash; Enzyme-linked immunosorbent assay (ELISA) is a third method used to detect anti-dsDNA antibodies [",
"      <a class=\"abstract\" href=\"UTD.htm?1/10/1192/abstract/20,21\">",
"       20,21",
"      </a>",
"      ]. In this method, the wells of a microtiter plate are coated with dsDNA, which serves as substrate to detect anti-dsDNA antibodies. Human antibodies are detected using an enzyme-conjugated secondary antiserum directed against human immunoglobulin. The enzyme catalyzes a chemical reaction that can be used to quantify the amount of anti-dsDNA antibodies. The dsDNA ELISA test is positive in approximately 70 to 80 percent of patients with SLE. The IgG antibody levels correlate moderately well with active nephritis, and there is a good correlation with disease activity in general. The specificity of a positive test by ELISA for the diagnosis of SLE is approximately 70 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?1/10/1192/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Fluorescent beads",
"      </strong>",
"      &mdash; A fourth method to detect anti-dsDNA antibodies involves the use of dsDNA coupled to fluorescent microspheres. The microspheres are incubated with patient serum and subsequently with phycoerythrin-conjugated secondary antiserum directed against human immunoglobulin. Flow cytometry is used to detect and quantify the level of fluorescence bound to the microspheres, and the level of fluorescence is related to the concentration in the serum [",
"      <a class=\"abstract\" href=\"UTD.htm?1/10/1192/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The sensitivity and specificity of each dsDNA antibody detection method for the diagnosis of SLE depend upon the quality of DNA substrate. The assay may detect antibodies directed against ssDNA, as well as dsDNA, if the dsDNA is partially denatured. The resulting assay may have increased sensitivity but decreased specificity for the diagnosis of SLE. In one study of 158 ANA-positive sera, the sensitivity and specificity of an ELISA for anti-dsDNA antibodies for the diagnosis of SLE were 79 and 73 percent. In contrast, the Crithidia luciliae assay was 41 percent sensitive and 99 percent specific for the diagnosis of SLE [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1192/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Occasionally, a patient will be unexpectedly found to have a positive test for anti-dsDNA antibodies but a negative ANA test. HEp-2 cells contain abundant dsDNA, and a positive test for anti-dsDNA antibodies should also result in a positive test for ANAs by IIF. However, because anti-dsDNA antibodies may be detected by a variety of assay techniques (as described above), it is possible that the anti-dsDNA assay used, such as the Farr, ELISA, or fluorescent bead assay, may be more sensitive than IIF on HEp-2 cell substrate for the detection of anti-dsDNA antibodies. The clinical significance of anti-dsDNA antibodies detected by one of these assays, in the setting of a negative test for ANA by IIF, is uncertain.",
"   </p>",
"   <p>",
"    A false-positive anti-dsDNA may be suspected when anti-dsDNA antibodies are detected by use of the Crithidia luciliae assay although the IIF assay for ANAs is negative. This can occur because complexes of low density lipoprotein and IgG may bind nonspecifically to the flagellate basal body [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1192/abstract/24\">",
"     24",
"    </a>",
"    ]. This false-positive test result using the Crithidia substrate may &ldquo;disappear&rdquo; if serum is obtained from the patient after overnight fasting.",
"   </p>",
"   <p>",
"    An ANA-negative and anti-dsDNA antibody-positive result is not possible if the clinical laboratory uses antigen-coated fluorescent microspheres as a screening test for ANAs; the dsDNA-coated microsphere is one of the panel of antigen-coated microspheres used to test for autoantibodies in such assays. Thus, the fluorescent bead ANA screening test would, by definition, be considered positive if anti-dsDNA antibodies are detected. It should be noted that the American College of Rheumatology recommends that solid phase assays should not be used as the initial test to detect ANAs. (See position statement at",
"    <a class=\"external\" href=\"file://www.rheumatology.org/practice/ana_position_stmt.pdf\">",
"     www.rheumatology.org/practice/ana_position_stmt.pdf",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because anti-dsDNA antibody tests have different sensitivities and specificities and because of the possibility of false positive results, it is important for clinicians to know which method is used by their clinical laboratory for the detection of anti-dsDNA antibodies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26100791\">",
"    <span class=\"h3\">",
"     Titer, pathogenicity, and disease activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is not clear why some patients with anti-dsDNA antibodies experience SLE flares while others do not. In the case of SLE glomerulonephritis, a number of properties of anti-dsDNA antibodies, including avidity for antigen, isoelectric point, isotype, ability to fix complement, and idiotype, may affect their pathogenicity. The location of immune complex deposition within the kidney and the amount of IgG anti-dsDNA antibody deposition may affect the degree of renal damage [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1192/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]. Some studies suggest that anti-dsDNA antibodies may crossreact with antigens present in the glomerulus and that these cross-reacting antibodies may contribute to disease pathogenesis.",
"   </p>",
"   <p>",
"    These antibody properties may vary from individual to individual, over time in the same individual, or with disease activity, even in the face of a stable antibody titer. Thus, there are some patients with SLE who have persistently elevated anti-dsDNA antibody measurements despite improvement in disease activity. Similarly, a small but significant minority of patients have active nephritis without elevations of anti-dsDNA antibody titer.",
"   </p>",
"   <p>",
"    Titers (in the case of the Crithidia luciliae assay) or concentrations (in the case of other assays) of anti-dsDNA antibodies may be helpful in the management of some patients with SLE. Anti-dsDNA antibodies tend to increase when disease is active, and there is a strong association between the level of anti-dsDNA antibodies and glomerulonephritis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1192/abstract/9,10\">",
"     9,10",
"    </a>",
"    ], particularly in the setting of hypocomplementemia [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1192/abstract/9,28\">",
"     9,28",
"    </a>",
"    ]. Some studies have reported exceptions to the association between anti-dsDNA antibody levels and disease activity; as an example, some patients have elevated levels of anti-dsDNA antibodies in the setting of inactive or minimally active lupus [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1192/abstract/29\">",
"     29",
"    </a>",
"    ]. Thus, while the correlation between antibody level and disease activity holds for some patients with SLE, there are other patients for whom this assay has limited clinical utility. For example, there is no relationship between antibody titer and disease activity for neuropsychiatric manifestations of SLE [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1192/abstract/30\">",
"     30",
"    </a>",
"    ]. In general, monitoring anti-dsDNA antibodies is most useful for those patients in whom changes in titer correlate with clinical status before or during flares [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1192/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Distinguishing a flare of SLE from intercurrent infectious diseases (eg, secondary to treatment with immunosuppressive agents), toxic effects of drugs, and unrelated diseases may be challenging. An increase in the level of anti-dsDNA antibodies may be helpful in some patients in making these distinctions. Although, as noted above, there is variability among patients, the test for anti-dsDNA antibodies becomes especially helpful when a given patient follows the characteristic pattern of rising anti-dsDNA antibodies and falling complement in the setting of a flare. However, once a particular patient shows a disassociation between anti-dsDNA antibody level and clinical evidence of nephritis, for example, subsequent changes in anti-dsDNA antibody levels are less likely to accurately reflect disease activity. In this setting, therapeutic decisions must be guided by the clinical picture and, perhaps, by other serological findings such as complement levels. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/38/41578?source=see_link&amp;anchor=H2#H2\">",
"     \"Overview of the therapy and prognosis of systemic lupus erythematosus in adults\", section on 'Determination of disease activity and severity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     ANTI-Sm AND ANTI-U1 RNP ANTIBODIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anti-Sm and anti-U1 RNP antigen-antibody systems are considered together because the antibodies frequently coexist in patients with SLE. In addition, the Sm and U1 RNP autoantigens co-localize in distinct cellular structures known as small nuclear ribonucleoprotein particles (snRNPs). Autoantibodies directed against Sm and U1 RNP antigens also produce similar (finely-speckled nuclear) staining patterns when detected by IIF using the HEp-2 cell substrate (",
"    <a class=\"graphic graphic_picture graphicRef59033 \" href=\"UTD.htm?10/20/10564\">",
"     picture 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Sm and U1 RNP antigens, together with the autoantigens Ro and La, are sometimes referred to as &ldquo;extractable nuclear antigens.&rdquo; This nomenclature is a remnant from early studies in which antigens were removed or &ldquo;extracted&rdquo; from a cellular substrate in a saline solution. The extracted antigens could then be used in Ouchterlony immunodiffusion or counterimmunoelectrophoresis assays to detect autoantibodies. Although agarose gel-based assays are rarely used to detect autoantibodies, the term &ldquo;extractable nuclear antigens&rdquo; continues to be frequently used when referring to Sm, U1 RNP, Ro, and La antigens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H158783\">",
"    <span class=\"h2\">",
"     Anti-Sm antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Sm antigens are nuclear, non-histone proteins that were initially characterized in 1966 by Eng Tan and were the first nuclear protein autoantigens to be described in SLE [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1192/abstract/32\">",
"     32",
"    </a>",
"    ]. The unusual name of this autoantibody-antigen system (&ldquo;Sm&rdquo;) reflects the tradition of naming antigens after the person (Stephanie Smith) whose serum was initially used to identify and characterize the proteins [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1192/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Anti-Sm antibodies bind to one or more of a series of Sm proteins designated SmB, SmD1, SmD2, SmD3, SmE, SmF, and SmG. The Sm proteins comprise a heptameric ring that forms a complex with small, uridine (U)-rich nuclear ribonucleic acids (RNAs) designated U1, U2, U4, and U5. The Sm proteins bind the U RNAs in the cytoplasm and are critical for the import of snRNPs into the nucleus [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1192/abstract/34\">",
"     34",
"    </a>",
"    ]. snRNPs have an important role in processing (&ldquo;splicing&rdquo;) precursor messenger (m)RNAs into mature mRNAs [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1192/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H158502\">",
"    <span class=\"h2\">",
"     Anti-U1 RNP antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anti-U1 RNP antibodies react with one or more of three proteins (70-kD, A, and C) that are specifically present in the U1 snRNP complex. Unlike the Sm antigens (which bind to U-rich RNAs U1, U2, U4, and U5), 70-kD, A, and C are only present in the U1 snRNP complex. Anti-U1 RNP antibodies are present in a subset of patients with SLE, and high titer anti-U1 RNP antibodies are present in all patients with mixed connective tissue disease, a disorder that is closely related to SLE. Anti-U1 RNP antibodies may also be present in lower titers in other rheumatic diseases, including primary Raynaud phenomenon, rheumatoid arthritis, and scleroderma [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1192/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/43/2743?source=see_link\">",
"     \"Anti-U1 RNP antibodies in mixed connective tissue disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Methods of measurement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Historically, anti-Sm and anti-U1 RNP antibodies were detected by immunodiffusion or counterimmunoelectrophoresis in agarose gels. These methods are relatively insensitive for the detection of autoantibodies, and it is difficult to use immunodiffusion to quantify antibody levels [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1192/abstract/32,36\">",
"     32,36",
"    </a>",
"    ]. Most clinical laboratories use &ldquo;solid-phase assays&rdquo; to detect these autoantibodies. Solid phase assays include the ELISA and flow cytometry-based assays described for the detection of anti-dsDNA antibodies above [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1192/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Anti-Sm and anti-U1 RNP antibodies'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H5\">",
"     'Measurement of anti-dsDNA'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H158253\">",
"    <span class=\"h2\">",
"     Clinical utility",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anti-Sm antibodies are insensitive but highly specific markers for SLE [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1192/abstract/38-40\">",
"     38-40",
"    </a>",
"    ]; anti-U1 RNP antibodies lack this specificity [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1192/abstract/35,40\">",
"     35,40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Anti-Sm antibodies may be detected in 10 to 50 percent of SLE patients, and estimates of specificity for SLE range from 55 to 100 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1192/abstract/38-40\">",
"     38-40",
"    </a>",
"    ]. Anti-Sm antibodies generally remain positive, even when a patient has entered remission. In contrast, the titer of anti-dsDNA antibodies may fall into the normal range when a patient&rsquo;s disease is quiescent. The detection of anti-Sm antibodies may, therefore, be especially useful diagnostically when a SLE patient&rsquo;s disease is relatively inactive.",
"   </p>",
"   <p>",
"    Anti-U1 RNP antibodies may be found in 3 to 69 percent of patients with SLE [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1192/abstract/35,40\">",
"     35,40",
"    </a>",
"    ]. High levels of anti-U1 RNP antibodies are always present in patients with mixed connective tissue disease (MCTD), because the presence of these antibodies is part of the definition of this disorder. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/23/3447?source=see_link\">",
"     \"Definition and diagnosis of mixed connective tissue disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The wide range of sensitivity and specificity of anti-Sm and anti-U1 RNP antibodies for the diagnosis of SLE reflects the variations in methods used to detect these antibodies. There is no single, standardized technique for producing and purifying Sm and U1 RNP antigens. Some assay kits use antigens that have been purified from cells in culture. Other assay kits may use recombinant antigens that have been prepared in prokaryotic or eukaryotic cells and that have then been purified. The presence of contaminating proteins in these preparations may greatly affect the performance of the assays. This is especially true because SLE patients frequently have high levels of antibodies directed against cellular and bacterial proteins. Serum antibodies directed against impurities in the autoantigen preparations may produce a false-positive test.",
"   </p>",
"   <p>",
"    There is also no consensus as to which autoantigens should be included in assay kits. For example, some commercial kits use only the U1 RNP 70-kD protein as the target for measuring anti-U1 RNP antibodies; other companies include all three of the U1 RNP autoantigens (70-kD, A, and C). In a patient who only has anti-U1 RNP antibodies directed against the A protein, testing only for antibodies against the 70-kD protein will produce a false-negative result.",
"   </p>",
"   <p>",
"    Because the preparation and purification of autoantigens are considered proprietary information, it is difficult for clinical immunology laboratories to predict and determine which commercial assay will perform the best in clinical practice. The limitations of tests for anti-Sm and anti-U1 RNP autoantibodies using solid-phase assays must be kept in mind when evaluating a patient who may have SLE.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?12/61/13265?source=see_link\">",
"       \"Patient information: Antinuclear antibodies (ANA) (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?28/35/29238?source=see_link\">",
"       \"Patient information: Systemic lupus erythematosus (SLE) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90749429\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antibodies to deoxyribonucleic acid (DNA) can be primarily divided into two groups: those reactive with denatured, single-stranded (ss)DNA and those recognizing native, double-stranded (ds)DNA. Anti-ssDNA antibodies, which react primarily with the purine and pyrimidine bases, are generally not useful in the diagnosis and management of SLE due to their low specificity for SLE and poor correlation with SLE disease activity. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Anti-DNA antibodies'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Anti-ssDNA antibodies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Anti-dsDNA antibodies are useful in the evaluation and management of patients with SLE because of their relatively high specificity for SLE, tendency to fluctuate with disease activity, and association with active glomerulonephritis. Methods for detection of anti-dsDNA include the Farr, Crithidia luciliae, enzyme linked immunosorbent (ELISA), and fluorescent microsphere assays. The sensitivity and specificity of each method for the diagnosis of SLE depend, in part, upon the quality of DNA substrate. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Anti-dsDNA antibodies'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Measurement of anti-dsDNA'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A number of properties of anti-dsDNA antibodies may affect their pathogenicity in the kidney, including avidity, isoelectric point, isotype, ability to fix complement, and idiotype. In addition, the location and amount of immune complex deposition in the kidney may affect disease pathogenesis. Testing for anti-dsDNA antibodies may be especially helpful in patients who exhibit the characteristic pattern of rising anti-dsDNA antibodies and falling complement in the setting of a flare with evidence of nephritis. However, this association is not present in some patients, for whom changes in anti-dsDNA antibody levels do not reflect disease activity. (See",
"      <a class=\"local\" href=\"#H26100791\">",
"       'Titer, pathogenicity, and disease activity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The anti-Sm and anti-U1 RNP antigen antibodies frequently coexist in patients with SLE and produce similar (finely-speckled nuclear) staining patterns when detected by indirect immunofluorescence using the HEp-2 cell substrate. The Sm and U1 RNP autoantigens co-localize in distinct cellular structures known as small nuclear ribonucleoprotein particles (snRNPs). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Anti-Sm and anti-U1 RNP antibodies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The Sm antigens are nuclear, non-histone proteins, which comprise a heptameric ring that forms a complex with small, uridine-rich nuclear RNAs to facilitate import of snRNPs into the nucleus, in which they are important in the processing of precursor mRNAs. Most clinical laboratories use solid-phase assays such as ELISA and flow cytometry-based assays to detect these autoantibodies. (See",
"      <a class=\"local\" href=\"#H158783\">",
"       'Anti-Sm antibodies'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H158502\">",
"       'Anti-U1 RNP antibodies'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Methods of measurement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Anti-Sm antibodies are relatively insensitive but highly specific markers for SLE and generally remain positive, even when a patient has entered remission. (See",
"      <a class=\"local\" href=\"#H158253\">",
"       'Clinical utility'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      High levels of anti-U1 RNP antibodies are always present, by definition, in patients with mixed connective tissue disease. Anti-U1 RNP antibodies may also be found in some patients with SLE. The wide range of sensitivity and specificity of anti-Sm and anti-U1 RNP antibodies for the diagnosis of SLE reflects the variations in methods used to detect these antibodies. (See",
"      <a class=\"local\" href=\"#H158253\">",
"       'Clinical utility'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H158268\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editors of UpToDate, Inc. would like to acknowledge Morris Reichlin, MD, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1192/abstract/1\">",
"      Isenberg DA, Manson JJ, Ehrenstein MR, Rahman A. Fifty years of anti-ds DNA antibodies: are we approaching journey's end? Rheumatology (Oxford) 2007; 46:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1192/abstract/2\">",
"      Hahn BH. Antibodies to DNA. N Engl J Med 1998; 338:1359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1192/abstract/3\">",
"      Koffler D, Agnello V, Winchester R, Kunkel HG. The occurrence of single-stranded DNA in the serum of patients with systemic lupus erythematosus and other diseases. J Clin Invest 1973; 52:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1192/abstract/4\">",
"      Miles S, Isenberg D. A review of serological abnormalities in relatives of SLE patients. Lupus 1993; 2:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1192/abstract/5\">",
"      Kavanaugh AF, Solomon DH, American College of Rheumatology Ad Hoc Committee on Immunologic Testing Guidelines. Guidelines for immunologic laboratory testing in the rheumatic diseases: anti-DNA antibody tests. Arthritis Rheum 2002; 47:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1192/abstract/6\">",
"      Nossent JC, Huysen V, Smeenk RJ, Swaak AJ. Low avidity antibodies to dsDNA as a diagnostic tool. Ann Rheum Dis 1989; 48:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1192/abstract/7\">",
"      Swaak AJ, Groenwold J, Bronsveld W. Predictive value of complement profiles and anti-dsDNA in systemic lupus erythematosus. Ann Rheum Dis 1986; 45:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1192/abstract/8\">",
"      ter Borg EJ, Horst G, Hummel EJ, et al. Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study. Arthritis Rheum 1990; 33:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1192/abstract/9\">",
"      Schur PH, Sandson J. Immunologic factors and clinical activity in systemic lupus erythematosus. N Engl J Med 1968; 278:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1192/abstract/10\">",
"      Rothfield NF, Stollar BD. The relation of immunoglobulin class, pattern of anti-nuclear antibody, and complement-fixing antibodies to DNA in sera from patients with systemic lupus erythematosus. J Clin Invest 1967; 46:1785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1192/abstract/11\">",
"      Cervera R, Khamashta MA, Font J, et al. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore) 1993; 72:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1192/abstract/12\">",
"      Cort&eacute;s-Hern&aacute;ndez J, Ordi-Ros J, Labrador M, et al. Antihistone and anti-double-stranded deoxyribonucleic acid antibodies are associated with renal disease in systemic lupus erythematosus. Am J Med 2004; 116:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1192/abstract/13\">",
"      Bootsma H, Spronk P, Derksen R, et al. Prevention of relapses in systemic lupus erythematosus. Lancet 1995; 345:1595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1192/abstract/14\">",
"      Nossent JC, Huysen V, Smeenk RJ, Swaak AJ. Low avidity antibodies to double stranded DNA in systemic lupus erythematosus: a longitudinal study of their clinical significance. Ann Rheum Dis 1989; 48:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1192/abstract/15\">",
"      Busch H, Reddy R, Rothblum L, Choi YC. SnRNAs, SnRNPs, and RNA processing. Annu Rev Biochem 1982; 51:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1192/abstract/16\">",
"      Hylkema MN, van Bruggen MC, ten Hove T, et al. Histone-containing immune complexes are to a large extent responsible for anti-dsDNA reactivity in the Farr assay of active SLE patients. J Autoimmun 2000; 14:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1192/abstract/17\">",
"      Aarden LA, de Groot ER, Feltkamp TE. Immunology of DNA. III. Crithidia luciliae, a simple substrate for the determination of anti-dsDNA with the immunofluorescence technique. Ann N Y Acad Sci 1975; 254:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1192/abstract/18\">",
"      Smeenk R, van der Lelij G, Aarden L. Avidity of antibodies to dsDNA: comparison of IFT on Crithidia luciliae, Farr assay, and PEG assay. J Immunol 1982; 128:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1192/abstract/19\">",
"      Crowe W, Kushner I, Clough JD, Vignos PJ Jr. Comparison of the Crithidia lucilia, millipore filter, Farr, and hemagglutination methods for detection of antibodies to DNA. Arthritis Rheum 1978; 21:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1192/abstract/20\">",
"      Miller TE, Lahita RG, Zarro VJ, et al. Clinical significance of anti-double-stranded DNA antibodies detected by a solid phase enzyme immunoassay. Arthritis Rheum 1981; 24:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1192/abstract/21\">",
"      Avi&ntilde;a-Zubieta JA, Galindo-Rodriguez G, Kwan-Yeung L, et al. Clinical evaluation of various selected ELISA kits for the detection of anti-DNA antibodies. Lupus 1995; 4:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1192/abstract/22\">",
"      Haugbro K, Nossent JC, Winkler T, et al. Anti-dsDNA antibodies and disease classification in antinuclear antibody positive patients: the role of analytical diversity. Ann Rheum Dis 2004; 63:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1192/abstract/23\">",
"      Binder SR. Autoantibody detection using multiplex technologies. Lupus 2006; 15:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1192/abstract/24\">",
"      Kumar V, Krasny S, Beutner EH. Specificity of the Crithidia luciliae method for detecting anti-DNA antibodies. Effect of absorption for lipoproteins. Immunol Invest 1985; 14:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1192/abstract/25\">",
"      Vlahakos DV, Foster MH, Adams S, et al. Anti-DNA antibodies form immune deposits at distinct glomerular and vascular sites. Kidney Int 1992; 41:1690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1192/abstract/26\">",
"      D'Andrea DM, Coupaye-Gerard B, Kleyman TR, et al. Lupus autoantibodies interact directly with distinct glomerular and vascular cell surface antigens. Kidney Int 1996; 49:1214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1192/abstract/27\">",
"      Chubick A, Sontheimer RD, Gilliam JN, Ziff M. An appraisal of tests for native DNA antibodies in connective tissue diseases. Clinical usefulness of Crithidia luciliae assay. Ann Intern Med 1978; 89:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1192/abstract/28\">",
"      Lloyd W, Schur PH. Immune complexes, complement, and anti-DNA in exacerbations of systemic lupus erythematosus (SLE). Medicine (Baltimore) 1981; 60:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1192/abstract/29\">",
"      Gladman DD, Urowitz MB, Keystone EC. Serologically active clinically quiescent systemic lupus erythematosus: a discordance between clinical and serologic features. Am J Med 1979; 66:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1192/abstract/30\">",
"      Winfield JB, Brunner CM, Koffler D. Serologic studies in patients with systemic lupus erythematosus and central nervous system dysfunction. Arthritis Rheum 1978; 21:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1192/abstract/31\">",
"      Ho A, Magder LS, Barr SG, Petri M. Decreases in anti-double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus. Arthritis Rheum 2001; 44:2342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1192/abstract/32\">",
"      Tan EM, Kunkel HG. Characteristics of a soluble nuclear antigen precipitating with sera of patients with systemic lupus erythematosus. J Immunol 1966; 96:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1192/abstract/33\">",
"      Tsokos GC. In the beginning was Sm. J Immunol 2006; 176:1295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1192/abstract/34\">",
"      Pannone BK, Wolin SL. Sm-like proteins wRING the neck of mRNA. Curr Biol 2000; 10:R478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1192/abstract/35\">",
"      Benito-Garcia E, Schur PH, Lahita R, American College of Rheumatology Ad Hoc Committee on Immunologic Testing Guidelines. Guidelines for immunologic laboratory testing in the rheumatic diseases: anti-Sm and anti-RNP antibody tests. Arthritis Rheum 2004; 51:1030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1192/abstract/36\">",
"      Kurata N, Tan EM. Identification of antibodies to nuclear acidic antigens by counterimmunoelectrophoresis. Arthritis Rheum 1976; 19:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1192/abstract/37\">",
"      Houtman PM, Kallenberg CG, Limburg PC, et al. Quantitation of antibodies to nucleoribonucleoprotein by ELISA: relation between antibody levels and disease activity in patients with connective tissue disease. Clin Exp Immunol 1985; 62:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1192/abstract/38\">",
"      Barada FA Jr, Andrews BS, Davis JS 4th, Taylor RP. Antibodies to Sm in patients with systemic lupus erythematosus. Correlation of Sm antibody titers with disease activity and other laboratory parameters. Arthritis Rheum 1981; 24:1236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1192/abstract/39\">",
"      Beaufils M, Kouki F, Mignon F, et al. Clinical significance of anti-Sm antibodies in systemic lupus erythematosus. Am J Med 1983; 74:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1192/abstract/40\">",
"      Phan TG, Wong RC, Adelstein S. Autoantibodies to extractable nuclear antigens: making detection and interpretation more meaningful. Clin Diagn Lab Immunol 2002; 9:1.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1814 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-BFBE39938F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_10_1192=[""].join("\n");
var outline_f1_10_1192=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H90749429\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H157844\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANTI-DNA ANTIBODIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Anti-ssDNA antibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Anti-dsDNA antibodies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Measurement of anti-dsDNA",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26100791\">",
"      - Titer, pathogenicity, and disease activity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ANTI-Sm AND ANTI-U1 RNP ANTIBODIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H158783\">",
"      Anti-Sm antibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H158502\">",
"      Anti-U1 RNP antibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Methods of measurement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H158253\">",
"      Clinical utility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H90749429\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H158268\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/1814\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/1814|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/32/42499\" title=\"picture 1\">",
"      HEp-2 cells stained homogeneous",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/20/10564\" title=\"picture 2\">",
"      HEp-2 cells stained speckled",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/43/2743?source=related_link\">",
"      Anti-U1 RNP antibodies in mixed connective tissue disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27718?source=related_link\">",
"      Antiribosomal P protein antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/23/3447?source=related_link\">",
"      Definition and diagnosis of mixed connective tissue disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/3/27706?source=related_link\">",
"      Diagnosis and classification of renal disease in systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/16/3338?source=related_link\">",
"      Diagnosis and differential diagnosis of systemic lupus erythematosus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/32/28168?source=related_link\">",
"      Drug-induced lupus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28520?source=related_link\">",
"      Measurement and clinical significance of antinuclear antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/44/42695?source=related_link\">",
"      Miscellaneous antinuclear antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/38/41578?source=related_link\">",
"      Overview of the therapy and prognosis of systemic lupus erythematosus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?12/61/13265?source=related_link\">",
"      Patient information: Antinuclear antibodies (ANA) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/35/29238?source=related_link\">",
"      Patient information: Systemic lupus erythematosus (SLE) (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_10_1193="SLE with end stage interstitial fibrosis chest x-ray";
var content_f1_10_1193=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F88485%7ERADIOL%2F88486&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F88485%7ERADIOL%2F88486&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 619px\">",
"   <div class=\"ttl\">",
"    End-stage interstitial fibrosis on chest radiography in systemic lupus erythematosus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 599px; height: 332px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The AP and lateral x-rays show bibasilar interstitial fibrosis and honeycombing in a 39-year-old female patient with longstanding diagnosis of SLE.",
"    <div class=\"footnotes\">",
"     AP: anteroposterior; SLE: systemic lupus erythematosus.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Joseph Farnam, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 617px\">",
"   <div class=\"ttl\">",
"    End-stage interstitial fibrosis on computerized tomography scan in systemic lupus erythematosus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 597px; height: 223px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Panel A:&nbsp;A small segmental region of honeycombing is demonstrated in this 39-year-old female with systemic lupus erythematosus&nbsp;in the anterior segment of the right upper lobe (arrow). Panel B: Extensive end-stage fibrosis and honeycombing&nbsp;are demonstrated in the lower lobes (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Joseph Farnam, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_10_1193=[""].join("\n");
var outline_f1_10_1193=null;
var title_f1_10_1194="Epidemiology, clinical manifestations, and diagnosis of tuberculosis in HIV-infected patients";
var content_f1_10_1194=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology, clinical manifestations, and diagnosis of tuberculosis in HIV-infected patients",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/10/1194/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/10/1194/contributors\">",
"     Gary Maartens, MBChB, MMed",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/10/1194/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/10/1194/contributors\">",
"     C Fordham von Reyn, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/10/1194/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/10/1194/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/10/1194/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 7, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The intersection of the HIV and tuberculosis (TB) epidemics has led to a dramatic upsurge in global TB incidence, resulting in remarkable increases in morbidity and mortality in some parts of the world. This is most notable in Africa, which carries one-third of all tuberculosis cases [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1194/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In developed countries, all forms of TB are regarded as AIDS-defining conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1194/abstract/2\">",
"     2",
"    </a>",
"    ]. In contrast, the World Health Organization staging system, used in most developing countries, still separates pulmonary TB (stage 3) from extrapulmonary TB (stage 4 or AIDS) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1194/abstract/3\">",
"     3",
"    </a>",
"    ]. Since TB commonly occurs in immunocompetent people, it is not surprising that TB occurs with a wide range of CD4 counts. The CD4 count largely determines the clinical and radiographic presentations of TB [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1194/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical features and diagnosis of TB in HIV-infected patients will be reviewed here. Prophylaxis and treatment of this disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/12/4298?source=see_link\">",
"     \"Treatment of latent tuberculosis infection in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/35/19002?source=see_link\">",
"     \"Treatment of pulmonary tuberculosis in the HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20477340\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A large burden of tuberculosis and HIV infections occurs in Africa. For example, South Africa has the third highest tuberculosis incidence in the world, with 948 cases per 100,000 people per year [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1194/abstract/6\">",
"     6",
"    </a>",
"    ] while the HIV prevalence among adults is approximately 20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1194/abstract/7\">",
"     7",
"    </a>",
"    ]. Among 825 patients who enrolled in an antiretroviral therapy (ART) program for HIV treatment in South Africa, 19 percent had evidence of TB infection on a screening sputum culture [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1194/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Interactions between HIV and tuberculosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dual infection with HIV and TB leads to reciprocal interactions that have significant clinical impact.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h3\">",
"     Effect of HIV on TB",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of TB increases after HIV seroconversion, doubling within the first year [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1194/abstract/9\">",
"     9",
"    </a>",
"    ], due to rapid depletion of TB-specific T helper cells, which occurs soon after HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1194/abstract/10\">",
"     10",
"    </a>",
"    ]. Thereafter, the risk of TB progressively increases with declining immunity [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1194/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. HIV-infected patients are at greatly increased risk of developing active TB from reactivated latent infection [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1194/abstract/13\">",
"     13",
"    </a>",
"    ]. TB incidence has increased greatly in Africa driven by the HIV epidemic [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1194/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HIV infection is also a risk factor for accelerated progression of TB following exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1194/abstract/15\">",
"     15",
"    </a>",
"    ], which has resulted in outbreaks of multidrug-resistant and extensively drug-resistant (XDR) tuberculosis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1194/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. One study reported that the calculated duration of TB disease prior to diagnosis was three times shorter in HIV-infected patients than in HIV-seronegative patients [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1194/abstract/15\">",
"     15",
"    </a>",
"    ]. Clinicians therefore need to be aware that in HIV-infected patients, TB is a more subacute than chronic illness, and that TB can progress rapidly while a diagnostic work up is being done. The shorter disease duration together with the higher proportion of sputum smear-negative TB seen with HIV infection results in a lower risk of TB transmission from HIV-infected patients with TB [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1194/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A positive HIV serostatus also confers risk of recurrent TB infection [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1194/abstract/20\">",
"     20",
"    </a>",
"    ], often due to exogenous reinfection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/55/17272?source=see_link\">",
"     \"Monitoring the HIV-infected patient on antituberculous medications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Effect of TB on HIV",
"    </span>",
"    &nbsp;&mdash;&nbsp;Likewise, TB seems to have a negative impact on HIV disease, increasing the risk of progression to AIDS or death following TB treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1194/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. The acceleration of HIV diseases by TB may result from one or more of the following mechanisms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      TB infection is associated with significant increases in plasma HIV viremia [",
"      <a class=\"abstract\" href=\"UTD.htm?1/10/1194/abstract/23\">",
"       23",
"      </a>",
"      ]. As is the case with other opportunistic infections, HIV viremia usually declines after initiation of successful TB treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?1/10/1194/abstract/24\">",
"       24",
"      </a>",
"      ]. However, for reasons that remain unclear, persistently high levels of viremia have been observed in patients from Africa despite initiation of effective antitubercular therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?1/10/1194/abstract/25,26\">",
"       25,26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Generalized immune activation, due to TB infection, may increase the proportion of CD4 cells that are preferential targets for HIV [",
"      <a class=\"abstract\" href=\"UTD.htm?1/10/1194/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Increased expression of the HIV coreceptors CCR5 and CXCR4 occurs in HIV-infected patients with TB co-infection [",
"      <a class=\"abstract\" href=\"UTD.htm?1/10/1194/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Impact of antiretroviral therapy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1240930045\">",
"    <span class=\"h3\">",
"     Effect on TB incidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The introduction of potent antiretroviral therapy (ART) has had a significant impact on the intersection of the HIV and TB epidemics [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1194/abstract/28\">",
"     28",
"    </a>",
"    ]. Immune recovery on ART is associated with a higher frequency of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/35/15924?source=see_link\">",
"     tuberculin skin test",
"    </a>",
"    positivity [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1194/abstract/28\">",
"     28",
"    </a>",
"    ] As is the case with other opportunistic infections, ART reduces the risk of developing TB, although incidence rates remain higher than in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1194/abstract/28-35\">",
"     28-35",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a clinical trial conducted in Haiti, 816 study participants with a baseline CD4 count between 200 and 350",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"      </span>",
"      were randomly assigned to &ldquo;early ART&rdquo; (within two weeks of enrollment) or to &ldquo;deferred ART&rdquo; (initiating ART based on time to onset of clinical AIDS or attainment of a CD4 cell count &lt;200",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"       )",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?1/10/1194/abstract/36\">",
"       36",
"      </a>",
"      ]. All patients received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"       isoniazid",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      for TB and Pneumocystis prophylaxis, respectively. There were 36 incident cases of TB in the deferred treatment group compared with 18 in the early treatment group (hazard ratio, 2.0; 95% CI 1.2-3.6).",
"     </li>",
"     <li>",
"      A meta-analysis of cohort studies reported a 67 percent reduction in the incidence of TB in patients who received ART (95% confidence interval 61 to 73 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/10/1194/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In an observational cohort study in South Africa, TB incidence was determined among 1554 patients on ART with a median follow-up period of 5 years [",
"      <a class=\"abstract\" href=\"UTD.htm?1/10/1194/abstract/34,38\">",
"       34,38",
"      </a>",
"      ]. A strong independent association was noted between the incidence of TB and CD4 cell counts on ART. TB incidence in patients in the CD4 count strata &lt;100 and &gt;700",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"      </span>",
"      was 25.5 and 2.7 per 100 person years respectively. However, TB incidence in the highest CD4 cell stratum of &gt;700",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"      </span>",
"      was still 4.4-fold higher than the incidence in HIV-uninfected individuals from the same community.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1240930352\">",
"    <span class=\"h3\">",
"     Starting ART in TB patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;ART dramatically reduces mortality and morbidity. Co-administration of ART and TB therapy is complicated by drug interactions, shared toxicity, high pill burden, and deterioration of TB symptoms and signs or the development of new features due to the immune reconstitution inflammatory syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1194/abstract/39\">",
"     39",
"    </a>",
"    ]. The timing of ART initiation in TB patients is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23098?source=see_link\">",
"     \"Immune reconstitution inflammatory syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/35/19002?source=see_link&amp;anchor=H33#H33\">",
"     \"Treatment of pulmonary tuberculosis in the HIV-infected patient\", section on 'Timing of ART in the treatment-naive patient'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of TB in the HIV-infected patient are heavily influenced by the degree of immunosuppression and are discussed below [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1194/abstract/5,40\">",
"     5,40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Pulmonary tuberculosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with TB and early HIV disease present in similar ways to HIV-seronegative patients, with cavitation in apical pulmonary areas. Symptoms of pulmonary TB include fever, cough, weight loss, night sweats and malaise. As immunity declines, the frequency of pulmonary cavitation, which is the hallmark of pulmonary TB in adults, becomes progressively less common [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1194/abstract/5,40\">",
"     5,40",
"    </a>",
"    ]. One consequence of the lower frequency of pulmonary cavitation in HIV infection is that hemoptysis occurs with lower frequency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Extrapulmonary disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of extrapulmonary and disseminated TB is greater in HIV-infected patients with advanced immunosuppression [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1194/abstract/4,12,41-43\">",
"     4,12,41-43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most common sites of extrapulmonary involvement are lymph nodes and pleura, but virtually any site can be involved [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1194/abstract/40,44,45\">",
"     40,44,45",
"    </a>",
"    ]. The following observations illustrate the frequency of the most common sites of extrapulmonary disease in HIV-infected patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Extrathoracic lymph nodes are involved in 18 to 22 percent of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?1/10/1194/abstract/4,44\">",
"       4,44",
"      </a>",
"      ]. The most common sites are the cervical (84 percent) and axillary nodes (18 percent).",
"     </li>",
"     <li>",
"      In a study of 464 patients with extrapulmonary TB, HIV-infected patients (n = 199) were more likely than control patients to have either mediastinal adenopathy, or disseminated, genitourinary, or intra-abdominal TB [",
"      <a class=\"abstract\" href=\"UTD.htm?1/10/1194/abstract/44\">",
"       44",
"      </a>",
"      ]. Involvement of the genitourinary system in HIV infection is usually a manifestation of disseminated disease.",
"     </li>",
"     <li>",
"      A case-control study of approximately 3000 patients with tuberculosis found that pleural involvement was more common among persons with CD4 counts &lt;200",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"      </span>",
"      than in HIV-infected patients with CD4 counts &gt;200",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"      </span>",
"      (11 versus 6 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/10/1194/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Disseminated tuberculosis may present as prolonged fever without pulmonary symptoms and is a common cause of death among hospitalized HIV-infected patients [",
"      <a class=\"abstract\" href=\"UTD.htm?1/10/1194/abstract/47,48\">",
"       47,48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a retrospective review of 320 hospitalizations for extrapulmonary TB, patients with HIV infection and low CD4 counts were more likely to have CNS TB and disseminated disease [",
"      <a class=\"abstract\" href=\"UTD.htm?1/10/1194/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5854742\">",
"    <span class=\"h2\">",
"     Subclinical infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subclinical tuberculosis is increasingly recognized in settings where sputum cultures are done for intensive case finding or TB prevalence surveys [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1194/abstract/49\">",
"     49",
"    </a>",
"    ]. Autopsy studies conducted in Africa, where diagnostic facilities are often limited to sputum smears, show that unsuspected TB is often present among patients dying with AIDS [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1194/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     RADIOGRAPHIC IMAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Imaging is a very important diagnostic modality in TB associated with HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1194/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Chest radiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;In classic pulmonary tuberculosis, upper lung fields are typically involved and pulmonary cavitation is very suggestive of the diagnosis. However, as immunity declines, patients are more likely to have atypical radiographic findings, including non-cavitary pulmonary infiltrates with no particular preference for the upper lung fields [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1194/abstract/5,40\">",
"     5,40",
"    </a>",
"    ] (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef79587 \" href=\"UTD.htm?9/36/9807\">",
"     image 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    One study evaluated 133 AIDS patients with TB at a single institution in New York City [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1194/abstract/5\">",
"     5",
"    </a>",
"    ]. Chest radiographs showed the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patterns typical for primary TB &mdash; 36 percent. These findings included pleural effusion, intrathoracic lymphadenopathy (mediastinum and hilum), or middle or lower lobe consolidation without cavitation.",
"     </li>",
"     <li>",
"      Patterns compatible with post-primary (reactivation) TB &mdash; 29 percent. These findings included",
"      <span class=\"nowrap\">",
"       apical/posterior",
"      </span>",
"      consolidation of the upper lobes or consolidation of the superior segments of the lower lobes (without adenopathy or effusion), endobronchial spread (acinar or 3 to 4 mm shadows, remote from a cavity or upper lobe consolidation), or bronchiectasis.",
"     </li>",
"     <li>",
"      A miliary pattern &mdash; 4 percent.",
"     </li>",
"     <li>",
"      Abnormalities atypical for TB, such as diffuse infiltrates suggestive of PCP &mdash; 13 percent.",
"     </li>",
"     <li>",
"      Minimal changes &mdash; 5 percent.",
"     </li>",
"     <li>",
"      Normal chest radiographs &mdash; 14 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most of the patients with CD4 counts greater than 200",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    showed post-primary patterns of disease (55 percent); only one such patient had a normal chest radiograph. In comparison, patients with fewer than 200 CD4",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    were nearly as likely to have normal chest radiographs (21 percent) as they were to have post-primary patterns (23 percent). This trend has been documented in other studies and should be kept in mind when faced with a symptomatic patient who has a normal chest radiograph [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1194/abstract/4,33,52-54\">",
"     4,33,52-54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Computed tomography",
"    </span>",
"    &nbsp;&mdash;&nbsp;CT scan of the chest is most useful in patients with suspected pulmonary TB who have normal or nonspecific abnormalities on chest radiograph. CT scans typically show more lesions than are visible on chest radiograph, and are particularly helpful in detecting lymphadenopathy. The intrathoracic adenopathy associated with TB in HIV-infected patients has a characteristic appearance on computed tomography (CT) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1194/abstract/55\">",
"     55",
"    </a>",
"    ]. The lymph nodes appear hypodense relative to soft tissue, and the rim is enhanced with contrast (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef67296 \" href=\"UTD.htm?32/48/33538\">",
"     image 2",
"    </a>",
"    ). Although this finding is not pathognomonic of TB, it is sufficiently characteristic that empiric therapy should be started pending results of cultures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Abdominal imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with clinical features suggestive of abdominal TB or patients with suspected TB and negative chest imaging should undergo abdominal imaging with either CT scan or ultrasonography. The most suggestive imaging feature supporting a diagnosis of TB is intra-abdominal lymphadenopathy, which may be hypodense in the center (as noted above with thoracic nodes) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1194/abstract/56\">",
"     56",
"    </a>",
"    ]. Other suggestive features include ascites, peritoneal thickening, small bowel thickening, and splenic hypodensities [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1194/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Gallium scanning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gallium scanning may be helpful diagnostically, since tuberculous lymph nodes are \"hot\" on these scans. In one report, nodal uptake on the gallium scan had a 73 percent positive predictive value and its absence a 93 percent negative predictive value for tuberculous adenopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1194/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In HIV-infected patients suspected of having TB, the most important diagnostic tests are repeated sputum samples for smear and culture and lymph node aspiration, when feasible. A normal chest x-ray does not eliminate the possibility of TB, so sputum samples should still be obtained in symptomatic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1194/abstract/59\">",
"     59",
"    </a>",
"    ]. The Xpert",
"    <span class=\"nowrap\">",
"     MTB/RIF",
"    </span>",
"    assay is also an important diagnostic tool capable of detecting both M. tuberculosis complex as well as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1194/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with signs of extrapulmonary disease, specimens of CSF, lymph nodes, or pleural or pericardial fluid should be sent for mycobacterial culture, depending on the clinical presentation. In patients with low CD4 counts (especially &lt;100",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     )",
"    </span>",
"    disseminated TB is common, and cultures of blood and urine should also be performed as these have a good yield in this setting. In a series of 75 patients with AIDS and TB, mycobacteremia was documented in nearly one-third of the patients [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1194/abstract/4\">",
"     4",
"    </a>",
"    ]. The prevalence rose to 49 percent in those with a CD4 count below 100",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     .",
"    </span>",
"    However, it should be noted that the incremental yield of non-sputum samples in HIV-infected patients screened for TB is low [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1194/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A discussion of the various diagnostic modalities follows below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5989329\">",
"    <span class=\"h2\">",
"     Tuberculin skin testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The utility of a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/35/15924?source=see_link\">",
"     tuberculin skin test",
"    </a>",
"    depends on the immune status of the patient:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A negative",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/35/15924?source=see_link\">",
"       tuberculin skin test",
"      </a>",
"      in a patient with AIDS does not rule out the diagnosis due to the high prevalence of false negative tests in patients with advanced immunosuppression [",
"      <a class=\"abstract\" href=\"UTD.htm?1/10/1194/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In an HIV-infected patient with relatively preserved CD4 cell counts (eg, CD4 count &gt;350",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"       )",
"      </span>",
"      a positive skin test in a patient with compatible symptoms and signs of TB is strongly suggestive of the diagnosis pending further evaluation in low TB prevalence settings. However, tuberculin skin testing is not of value for diagnosing active TB in adults in areas where TB prevalence is high because the prevalence of positive skin tests is also high.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A positive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/35/15924?source=see_link\">",
"     tuberculin skin test",
"    </a>",
"    is also an indication for preventive therapy once active TB has been excluded. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/12/4298?source=see_link\">",
"     \"Treatment of latent tuberculosis infection in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5989944\">",
"    <span class=\"h2\">",
"     Clinical specimens",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5988868\">",
"    <span class=\"h3\">",
"     Pulmonary specimens",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h4\">",
"     Sputum",
"    </span>",
"    &nbsp;&mdash;&nbsp;At least two samples of expectorated sputum should be collected in all AIDS patients with suspected TB, preferably early in the morning on different days. A study in Southeast Asia found that the incremental yield of performing a third sputum smear over two smears was only 2 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1194/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sputum induction by ultrasonic nebulization of hypertonic saline is often performed on patients unable to produce expectorated sputum and is also a useful method if sputum is smear-negative. In a prospective South African study of 147 patients with suspected TB, induced sputum was smear-positive in 33 (27 percent) and culture-positive in 86 of 119 (72 percent) HIV-infected patients who had either negative smears on spontaneously produced sputum or who were unable to produce sputum [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1194/abstract/62\">",
"     62",
"    </a>",
"    ]. The yield was similar in patients with and without pulmonary infiltrates on chest radiography.",
"   </p>",
"   <p>",
"    A study of 44 HIV-positive patients in Brazil reported 98 percent agreement between AFB smear results and 86 percent agreement between culture results when a single induced sputum was compared with bronchoalveolar lavage results [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1194/abstract/63\">",
"     63",
"    </a>",
"    ]. In this series, the positive predictive value for M. tuberculosis of a positive AFB smear on induced sputum was 100 percent. This study suggests that induced sputum may represent an attractive alternative to bronchoscopy, especially in resource-poor areas with high TB prevalence.",
"   </p>",
"   <p>",
"    Induced sputum can yield positive cultures in 50 percent of patients with tuberculous effusions, with no other evidence of parenchymal disease on chest radiograph [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1194/abstract/64\">",
"     64",
"    </a>",
"    ]. In one series of 84 patients with tuberculous effusions there were 64 patients without parenchymal opacities, including 10 patients who were HIV-infected. Cultures of induced sputum were positive for tuberculosis for 27 of the 64 patients (42 percent), including five of the 10 (50 percent) HIV-infected patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/56/9098?source=see_link\">",
"     \"Diagnosis of pulmonary tuberculosis in HIV-negative patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5989513\">",
"    <span class=\"h4\">",
"     Bronchoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although bronchoscopy is an unattractive method of diagnosing TB because it creates aerosols of infectious droplets and places the practitioner at great risk of infection, it is a sensitive technique for diagnosing TB. An immediate diagnosis can be made from AFB smears in about one-half of patients, and the sensitivity of cultures approaches 100 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1194/abstract/65\">",
"     65",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/43/20154?source=see_link\">",
"     \"Approach to the HIV-infected patient with pulmonary symptoms\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5988963\">",
"    <span class=\"h4\">",
"     Thoracentesis and pleural biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;When present, tuberculous pleural disease is readily diagnosed by thoracentesis and pleural biopsy.",
"   </p>",
"   <p>",
"    An AFB smear of pleural fluid is positive in only about 15 percent of cases, but pleural fluid cultures have a higher yield in patients with AIDS compared with those without AIDS (60 to 90 percent versus 15 to 60 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1194/abstract/46,66,67\">",
"     46,66,67",
"    </a>",
"    ]. In high-prevalence settings, the finding of a lymphocytic exudate is usually considered grounds for commencing antitubercular therapy.",
"   </p>",
"   <p>",
"    When the diagnosis is unclear a pleural biopsy should be performed to make the diagnosis more rapidly. Biopsies show AFB in 69 percent of patients and granulomata in 88 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1194/abstract/66\">",
"     66",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/47/22261?source=see_link\">",
"     \"Tuberculous pleural effusions in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5990090\">",
"    <span class=\"h3\">",
"     Other clinical specimens",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5990098\">",
"    <span class=\"h4\">",
"     Lymph node aspiration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Needle aspiration of enlarged peripheral lymph nodes is a simple test with a high yield, and can provide a rapid diagnosis of TB. Among patients with extrapulmonary lymph node enlargement, fine needle aspiration was positive in 77 percent of cases, and biopsy with culture increased the yield to 96 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1194/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A 19 gauge or 18 gauge needle should be used and two slides prepared, one fixed for cytology and one air-dried for AFB staining. AFB are found in around 75 percent of patients with TB [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1194/abstract/68,69\">",
"     68,69",
"    </a>",
"    ], even if the lymphadenopathy is symmetrical [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1194/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5990119\">",
"    <span class=\"h4\">",
"     Other sites",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genitourinary TB rarely occurs in the absence of other sites of extrapulmonary disease, although it is frequently involved in disseminated TB, even in the absence of pyuria. In one series, for example, 61 of 79 (77 percent) HIV-infected patients with extrapulmonary TB whose urine was sent for culture grew M. tuberculosis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1194/abstract/44\">",
"     44",
"    </a>",
"    ]. Urine samples are easy to obtain and have good yield for diagnosing disseminated TB; a first morning urine sample on three consecutive days should be collected for mycobacterial culture.",
"   </p>",
"   <p>",
"    Stool cultures are helpful to diagnose MAC infection, but are less useful for diagnosing TB. M. tuberculosis in the stool is usually derived from swallowed mucus and represents pulmonary rather than enteric TB [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1194/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other sites should be sampled according to the signs and symptoms referable to the organ system. The central nervous system is frequently involved in disseminated TB [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1194/abstract/5,40\">",
"     5,40",
"    </a>",
"    ]. Given the number of opportunistic infections affecting the central nervous system in AIDS, there should be a low threshold for collecting CSF.",
"   </p>",
"   <p>",
"    In a patient with suspected miliary disease and a negative sputum examination, bone marrow biopsy as well as blood cultures should be performed [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1194/abstract/71\">",
"     71",
"    </a>",
"    ]. Blood cultures are positive in 49 percent of patients with disseminated disease and CD4 counts less than",
"    <span class=\"nowrap\">",
"     100/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1194/abstract/4\">",
"     4",
"    </a>",
"    ]. Mycobacterium tuberculosis is the most common cause of bloodstream infection in some areas in which both HIV and tuberculosis are epidemic [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1194/abstract/72\">",
"     72",
"    </a>",
"    ]. Liver biopsy has a very high yield in disseminated TB [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1194/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5989552\">",
"    <span class=\"h2\">",
"     Diagnostic microbiology",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5989892\">",
"    <span class=\"h3\">",
"     Sputum smear and culture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some studies show HIV-infected patients are more likely to have smear-negative pulmonary or extrapulmonary disease [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1194/abstract/73,74\">",
"     73,74",
"    </a>",
"    ]. A wide range of acid-fast smear positivity has been reported (31 to 81 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1194/abstract/75\">",
"     75",
"    </a>",
"    ]. In a study from South Africa among 584 HIV-infected patients, only one-third of the 116 positive cultures were smear-positive [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1194/abstract/76\">",
"     76",
"    </a>",
"    ]. In a study from Tanzania, a minority of patients who required treatment for suspected TB had positive microbiology (eg, AFB smear or culture) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1194/abstract/77\">",
"     77",
"    </a>",
"    ]. Smear-negative pulmonary TB occurs more commonly in HIV-infected patients because of their lower prevalence of pulmonary cavities. The yield on sputum culture is substantially higher (85 to 100 percent), since culture can detect as few as ten bacteria per mL of sputum [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1194/abstract/73,78\">",
"     73,78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients infected with HIV, a positive smear for acid-fast bacilli (AFB) is very specific for Mycobacterium tuberculosis, even in a setting with a high incidence of Mycobacterium avium complex (MAC), which will stain similarly. At San Francisco General Hospital, for example, 248 of 271 (92 percent) expectorated sputum samples that were positive for AFB grew M. tuberculosis on culture [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1194/abstract/79\">",
"     79",
"    </a>",
"    ]. This value is comparable to that found in HIV-negative patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5989687\">",
"    <span class=\"h3\">",
"     Fluorescence microscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;An alternative to Ziehl-Neelsen staining is examination with fluorescence microscopy, which has comparable specificity but has about 10 percent greater sensitivity [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1194/abstract/73\">",
"     73",
"    </a>",
"    ]. Studies in Kenya and Uganda demonstrated that the increased sensitivity of this test was cost-effective and expedited diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1194/abstract/80,81\">",
"     80,81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In resource-limited settings, innovative techniques have been investigated to determine if the utility of fluorescence microscopy may be improved by the use of low-cost light-emitting diode (LED), which has a lifespan of more than 50,000 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1194/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5989914\">",
"    <span class=\"h3\">",
"     Molecular tests",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5989591\">",
"    <span class=\"h4\">",
"     Nucleic acid amplification assays",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nucleic acid amplification assays are used to amplify the quantity of M. tuberculosis DNA in diagnostic specimens. These techniques are sensitive for the rapid detection of M. tuberculosis in a variety of specimens, including blood, sputum, and urine, usually in amounts too small to be seen by routine staining techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1194/abstract/82,83\">",
"     82,83",
"    </a>",
"    ]. A positive nucleic acid amplification assay in a patient with smear-positive AFB likely represents TB [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1194/abstract/59\">",
"     59",
"    </a>",
"    ]. However, in a patient with smear-negative TB, nucleic acid amplification testing appears to have lower sensitivity [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1194/abstract/84\">",
"     84",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/56/9098?source=see_link&amp;anchor=H15#H15\">",
"     \"Diagnosis of pulmonary tuberculosis in HIV-negative patients\", section on 'Nucleic acid amplification'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5989929\">",
"    <span class=\"h4\">",
"     Xpert MTB/RIF assay",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Xpert",
"    <span class=\"nowrap\">",
"     MTB/RIF",
"    </span>",
"    assay is an automated nucleic acid amplification test that can identify both presence of M. tuberculosis as well as presence of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    resistance. The assay is accurate and feasible to use in resource limited settings and among HIV-infected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1194/abstract/60,85\">",
"     60,85",
"    </a>",
"    ]. It has the potential to dramatically reduce the time to diagnosis and the time to initiation of effective therapy, although it requires a reliable power supply and operating temperatures below 30&deg;C.",
"   </p>",
"   <p>",
"    An important limitation of the test is its inability to determine which patients with pulmonary tuberculosis have sputum positive for acid-fast bacilli (AFB) on microscopy, a tool used to guide infection control practices, contact investigations, and monitor response to treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1194/abstract/86\">",
"     86",
"    </a>",
"    ]. The assay does generate quantitative polymerase chain reaction cycle-threshold (C",
"    <sub>",
"     T",
"    </sub>",
"    ) values, which are continuous variables inversely correlated with the number of copies of MTB complex rpoB gene. In a preliminary study including 496 patients with suspected tuberculosis in South Africa (where the prevalence of HIV is high), the C",
"    <sub>",
"     T",
"    </sub>",
"    (cut point &gt;31.8) was moderately useful for ruling out smear positivity (negative predictive value 80 percent), although the clinical utility for ruling in smear positivity was low [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1194/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5149409\">",
"    <span class=\"h3\">",
"     Urine antigen detection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Detection of the mycobacterial antigen lipoarabinomannan (LAM) in the urine may be a useful diagnostic assay. Urine LAM reflects disseminated TB and&nbsp;is more likely to be detected in HIV-infected&nbsp;patients with lower CD4 counts, especially inpatients [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1194/abstract/88-90\">",
"     88-90",
"    </a>",
"    ]. In one meta-analysis of HIV-infected patients, use of a urine LAM detection assay had sensitivity and specificity of 56 and 95 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1194/abstract/88\">",
"     88",
"    </a>",
"    ]. The sensitivity of the assay is low in HIV-negative patients. Further study of this assay is needed, including evaluation of the appropriate cut point for a positive result on point-of-care urine test strips [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1194/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Drug resistance testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;For all patients, testing for susceptibility to first-line agents should be performed if this is affordable to optimize efficacy of the therapeutic regimen and to decrease transmission of drug-resistant TB [",
"    <a class=\"abstract\" href=\"UTD.htm?1/10/1194/abstract/76\">",
"     76",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/52/32586?source=see_link\">",
"     \"Diagnosis, treatment, and prevention of drug-resistant tuberculosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The intersection of the HIV and tuberculosis (TB) epidemics has led to a dramatic surge in global TB incidence, resulting in remarkable increases in morbidity and mortality in some parts of the world. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The risk of TB increases with progressive immunosuppression. Likewise, TB has a negative impact on HIV disease, increasing the risk of AIDS or death. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Interactions between HIV and tuberculosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antiretroviral therapy reduces the risk of developing TB, although incidence rates remain higher than in the general population. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Impact of antiretroviral therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The risk of extrapulmonary and disseminated TB is greater in HIV-infected patients with advanced immunosuppression. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HIV-infected patients with advanced immunosuppression can have atypical chest radiography, including non-cavitary pulmonary infiltrates with no particular preference for the upper lung fields; normal chest x-rays can occur in 15 percent of patients. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Radiographic imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In HIV-infected patients suspected of having TB, the most important diagnostic tests are repeated sputum samples for smear and culture, and lymph node aspiration, when feasible. The Xpert",
"      <span class=\"nowrap\">",
"       MTB/RIF",
"      </span>",
"      assay is also an important tool for rapid diagnosis of tuberculosis as well as presence of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      resistance. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1194/abstract/1\">",
"      Chaisson RE, Martinson NA. Tuberculosis in Africa--combating an HIV-driven crisis. N Engl J Med 2008; 358:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1194/abstract/2\">",
"      From the Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. JAMA 1993; 269:729.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization. WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children. WHO Press, Geneva, Switzerland 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1194/abstract/4\">",
"      Jones BE, Young SM, Antoniskis D, et al. Relationship of the manifestations of tuberculosis to CD4 cell counts in patients with human immunodeficiency virus infection. Am Rev Respir Dis 1993; 148:1292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1194/abstract/5\">",
"      Greenberg SD, Frager D, Suster B, et al. Active pulmonary tuberculosis in patients with AIDS: spectrum of radiographic findings (including a normal appearance). Radiology 1994; 193:115.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.who.int/tb/publications/global_report/2009/update/tbu_9.pdf (Accessed on September 28, 2010).",
"    </li>",
"    <li>",
"     file://www.who.int/globalatlas/predefinedReports/EFS2008/short/EFSCountryProfiles2008_ZA.pdf (Accessed on September 28, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1194/abstract/8\">",
"      Bassett IV, Wang B, Chetty S, et al. Intensive tuberculosis screening for HIV-infected patients starting antiretroviral therapy in Durban, South Africa. Clin Infect Dis 2010; 51:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1194/abstract/9\">",
"      Sonnenberg P, Glynn JR, Fielding K, et al. How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort study in South African gold miners. J Infect Dis 2005; 191:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1194/abstract/10\">",
"      Geldmacher C, Schuetz A, Ngwenyama N, et al. Early depletion of Mycobacterium tuberculosis-specific T helper 1 cell responses after HIV-1 infection. J Infect Dis 2008; 198:1590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1194/abstract/11\">",
"      Wood R, Maartens G, Lombard CJ. Risk factors for developing tuberculosis in HIV-1-infected adults from communities with a low or very high incidence of tuberculosis. J Acquir Immune Defic Syndr 2000; 23:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1194/abstract/12\">",
"      Holmes CB, Wood R, Badri M, et al. CD4 decline and incidence of opportunistic infections in Cape Town, South Africa: implications for prophylaxis and treatment. J Acquir Immune Defic Syndr 2006; 42:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1194/abstract/13\">",
"      Selwyn PA, Hartel D, Lewis VA, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989; 320:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1194/abstract/14\">",
"      Corbett EL, Watt CJ, Walker N, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 2003; 163:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1194/abstract/15\">",
"      Corbett EL, Charalambous S, Moloi VM, et al. Human immunodeficiency virus and the prevalence of undiagnosed tuberculosis in African gold miners. Am J Respir Crit Care Med 2004; 170:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1194/abstract/16\">",
"      Shuchman M. Improving global health--Margaret Chan at the WHO. N Engl J Med 2007; 356:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1194/abstract/17\">",
"      Daley CL, Small PM, Schecter GF, et al. An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus. An analysis using restriction-fragment-length polymorphisms. N Engl J Med 1992; 326:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1194/abstract/18\">",
"      Gandhi NR, Moll A, Sturm AW, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006; 368:1575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1194/abstract/19\">",
"      Behr MA, Warren SA, Salamon H, et al. Transmission of Mycobacterium tuberculosis from patients smear-negative for acid-fast bacilli. Lancet 1999; 353:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1194/abstract/20\">",
"      Lahey T, Mackenzie T, Arbeit RD, et al. Recurrent tuberculosis risk among HIV-infected adults in Tanzania with prior active tuberculosis. Clin Infect Dis 2013; 56:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1194/abstract/21\">",
"      L&oacute;pez-Gatell H, Cole SR, Hessol NA, et al. Effect of tuberculosis on the survival of women infected with human immunodeficiency virus. Am J Epidemiol 2007; 165:1134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1194/abstract/22\">",
"      Badri M, Ehrlich R, Wood R, et al. Association between tuberculosis and HIV disease progression in a high tuberculosis prevalence area. Int J Tuberc Lung Dis 2001; 5:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1194/abstract/23\">",
"      Toossi Z, Mayanja-Kizza H, Hirsch CS, et al. Impact of tuberculosis (TB) on HIV-1 activity in dually infected patients. Clin Exp Immunol 2001; 123:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1194/abstract/24\">",
"      Goletti D, Weissman D, Jackson RW, et al. Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation. J Immunol 1996; 157:1271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1194/abstract/25\">",
"      Wolday D, Tegbaru B, Kassu A, et al. Expression of chemokine receptors CCR5 and CXCR4 on CD4+ T cells and plasma chemokine levels during treatment of active tuberculosis in HIV-1-coinfected patients. J Acquir Immune Defic Syndr 2005; 39:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1194/abstract/26\">",
"      Wolday D, Hailu B, Girma M, et al. Low CD4+ T-cell count and high HIV viral load precede the development of tuberculosis disease in a cohort of HIV-positive ethiopians. Int J Tuberc Lung Dis 2003; 7:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1194/abstract/27\">",
"      Vanham G, Edmonds K, Qing L, et al. Generalized immune activation in pulmonary tuberculosis: co-activation with HIV infection. Clin Exp Immunol 1996; 103:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1194/abstract/28\">",
"      Lawn SD, Bekker LG, Wood R. How effectively does HAART restore immune responses to Mycobacterium tuberculosis? Implications for tuberculosis control. AIDS 2005; 19:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1194/abstract/29\">",
"      Badri M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet 2002; 359:2059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1194/abstract/30\">",
"      Girardi E, Antonucci G, Vanacore P, et al. Impact of combination antiretroviral therapy on the risk of tuberculosis among persons with HIV infection. AIDS 2000; 14:1985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1194/abstract/31\">",
"      Girardi E, Sabin CA, d'Arminio Monforte A, et al. Incidence of Tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America. Clin Infect Dis 2005; 41:1772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1194/abstract/32\">",
"      Lawn SD, Badri M, Wood R. Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a South African cohort. AIDS 2005; 19:2109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1194/abstract/33\">",
"      Keiper MD, Beumont M, Elshami A, et al. CD4 T lymphocyte count and the radiographic presentation of pulmonary tuberculosis. A study of the relationship between these factors in patients with human immunodeficiency virus infection. Chest 1995; 107:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1194/abstract/34\">",
"      Gupta A, Wood R, Kaplan R, et al. Tuberculosis incidence rates during 8 years of follow-up of an antiretroviral treatment cohort in South Africa: comparison with rates in the community. PLoS One 2012; 7:e34156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1194/abstract/35\">",
"      HIV-CAUSAL Collaboration. Impact of antiretroviral therapy on tuberculosis incidence among HIV-positive patients in high-income countries. Clin Infect Dis 2012; 54:1364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1194/abstract/36\">",
"      Severe P, Juste MA, Ambroise A, et al. Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. N Engl J Med 2010; 363:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1194/abstract/37\">",
"      Lawn SD, Wood R, De Cock KM, et al. Antiretrovirals and isoniazid preventive therapy in the prevention of HIV-associated tuberculosis in settings with limited health-care resources. Lancet Infect Dis 2010; 10:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1194/abstract/38\">",
"      Lawn SD, Myer L, Edwards D, et al. Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa. AIDS 2009; 23:1717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1194/abstract/39\">",
"      McIlleron H, Meintjes G, Burman WJ, Maartens G. Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome. J Infect Dis 2007; 196 Suppl 1:S63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1194/abstract/40\">",
"      Barnes PF, Bloch AB, Davidson PT, Snider DE Jr. Tuberculosis in patients with human immunodeficiency virus infection. N Engl J Med 1991; 324:1644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1194/abstract/41\">",
"      Yang Z, Kong Y, Wilson F, et al. Identification of risk factors for extrapulmonary tuberculosis. Clin Infect Dis 2004; 38:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1194/abstract/42\">",
"      Leeds IL, Magee MJ, Kurbatova EV, et al. Site of extrapulmonary tuberculosis is associated with HIV infection. Clin Infect Dis 2012; 55:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1194/abstract/43\">",
"      Naing C, Mak JW, Maung M, et al. Meta-analysis: the association between HIV infection and extrapulmonary tuberculosis. Lung 2013; 191:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1194/abstract/44\">",
"      Shafer RW, Kim DS, Weiss JP, Quale JM. Extrapulmonary tuberculosis in patients with human immunodeficiency virus infection. Medicine (Baltimore) 1991; 70:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1194/abstract/45\">",
"      Hudson CP, Wood R, Maartens G. Diagnosing HIV-associated tuberculosis: reducing costs and diagnostic delay. Int J Tuberc Lung Dis 2000; 4:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1194/abstract/46\">",
"      Frye MD, Pozsik CJ, Sahn SA. Tuberculous pleurisy is more common in AIDS than in non-AIDS patients with tuberculosis. Chest 1997; 112:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1194/abstract/47\">",
"      Ansari NA, Kombe AH, Kenyon TA, et al. Pathology and causes of death in a group of 128 predominantly HIV-positive patients in Botswana, 1997-1998. Int J Tuberc Lung Dis 2002; 6:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1194/abstract/48\">",
"      von Reyn CF, Kimambo S, Mtei L, et al. Disseminated tuberculosis in human immunodeficiency virus infection: ineffective immunity, polyclonal disease and high mortality. Int J Tuberc Lung Dis 2011; 15:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1194/abstract/49\">",
"      Mtei L, Matee M, Herfort O, et al. High rates of clinical and subclinical tuberculosis among HIV-infected ambulatory subjects in Tanzania. Clin Infect Dis 2005; 40:1500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1194/abstract/50\">",
"      Havlir DV, Getahun H, Sanne I, Nunn P. Opportunities and challenges for HIV care in overlapping HIV and TB epidemics. JAMA 2008; 300:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1194/abstract/51\">",
"      Sterling TR, Pham PA, Chaisson RE. HIV infection-related tuberculosis: clinical manifestations and treatment. Clin Infect Dis 2010; 50 Suppl 3:S223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1194/abstract/52\">",
"      Diagnostic Standards and Classification of Tuberculosis in Adults and Children. This official statement of the American Thoracic Society and the Centers for Disease Control and Prevention was adopted by the ATS Board of Directors, July 1999. This statement was endorsed by the Council of the Infectious Disease Society of America, September 1999. Am J Respir Crit Care Med 2000; 161:1376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1194/abstract/53\">",
"      Lessnau KD, Gorla M, Talavera W. Radiographic findings in HIV-positive patients with sensitive and resistant tuberculosis. Chest 1994; 106:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1194/abstract/54\">",
"      Perlman DC, el-Sadr WM, Nelson ET, et al. Variation of chest radiographic patterns in pulmonary tuberculosis by degree of human immunodeficiency virus-related immunosuppression. The Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). The AIDS Clinical Trials Group (ACTG). Clin Infect Dis 1997; 25:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1194/abstract/55\">",
"      Pastores SM, Naidich DP, Aranda CP, et al. Intrathoracic adenopathy associated with pulmonary tuberculosis in patients with human immunodeficiency virus infection. Chest 1993; 103:1433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1194/abstract/56\">",
"      Koh DM, Burn PR, Mathews G, et al. Abdominal computed tomographic findings of Mycobacterium tuberculosis and Mycobacterium avium intracellulare infection in HIV seropositive patients. Can Assoc Radiol J 2003; 54:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1194/abstract/57\">",
"      Sinkala E, Gray S, Zulu I, et al. Clinical and ultrasonographic features of abdominal tuberculosis in HIV positive adults in Zambia. BMC Infect Dis 2009; 9:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1194/abstract/58\">",
"      Sant&iacute;n M, Podzamczer D, Ricart I, et al. Utility of the gallium-67 citrate scan for the early diagnosis of tuberculosis in patients infected with the human immunodeficiency virus. Clin Infect Dis 1995; 20:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1194/abstract/59\">",
"      Kaplan JE, Benson C, Holmes KH, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1194/abstract/60\">",
"      O'Grady J, Bates M, Chilukutu L, et al. Evaluation of the Xpert MTB/RIF assay at a tertiary care referral hospital in a setting where tuberculosis and HIV infection are highly endemic. Clin Infect Dis 2012; 55:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1194/abstract/61\">",
"      Monkongdee P, McCarthy KD, Cain KP, et al. Yield of acid-fast smear and mycobacterial culture for tuberculosis diagnosis in people with human immunodeficiency virus. Am J Respir Crit Care Med 2009; 180:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1194/abstract/62\">",
"      Wilson D, Nachega J, Morroni C, et al. Diagnosing smear-negative tuberculosis using case definitions and treatment response in HIV-infected adults. Int J Tuberc Lung Dis 2006; 10:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1194/abstract/63\">",
"      Conde MB, Soares SL, Mello FC, et al. Comparison of sputum induction with fiberoptic bronchoscopy in the diagnosis of tuberculosis: experience at an acquired immune deficiency syndrome reference center in Rio de Janeiro, Brazil. Am J Respir Crit Care Med 2000; 162:2238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1194/abstract/64\">",
"      Conde MB, Loivos AC, Rezende VM, et al. Yield of sputum induction in the diagnosis of pleural tuberculosis. Am J Respir Crit Care Med 2003; 167:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1194/abstract/65\">",
"      Salzman SH, Schindel ML, Aranda CP, et al. The role of bronchoscopy in the diagnosis of pulmonary tuberculosis in patients at risk for HIV infection. Chest 1992; 102:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1194/abstract/66\">",
"      Relkin F, Aranda CP, Garay SM, et al. Pleural tuberculosis and HIV infection. Chest 1994; 105:1338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1194/abstract/67\">",
"      Seibert AF, Haynes J Jr, Middleton R, Bass JB Jr. Tuberculous pleural effusion. Twenty-year experience. Chest 1991; 99:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1194/abstract/68\">",
"      Bem C, Patil PS, Elliott AM, et al. The value of wide-needle aspiration in the diagnosis of tuberculous lymphadenitis in Africa. AIDS 1993; 7:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1194/abstract/69\">",
"      Pithie AD, Chicksen B. Fine-needle extrathoracic lymph-node aspiration in HIV-associated sputum-negative tuberculosis. Lancet 1992; 340:1504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1194/abstract/70\">",
"      Bem C. Human immunodeficiency virus-positive tuberculous lymphadenitis in Central Africa: clinical presentation of 157 cases. Int J Tuberc Lung Dis 1997; 1:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1194/abstract/71\">",
"      Munseri PJ, Talbot EA, Bakari M, et al. The bacteraemia of disseminated tuberculosis among HIV-infected patients with prolonged fever in Tanzania. Scand J Infect Dis 2011; 43:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1194/abstract/72\">",
"      Archibald LK, den Dulk MO, Pallangyo KJ, Reller LB. Fatal Mycobacterium tuberculosis bloodstream infections in febrile hospitalized adults in Dar es Salaam, Tanzania. Clin Infect Dis 1998; 26:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1194/abstract/73\">",
"      Reid MJ, Shah NS. Approaches to tuberculosis screening and diagnosis in people with HIV in resource-limited settings. Lancet Infect Dis 2009; 9:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1194/abstract/74\">",
"      Harries AD. Tuberculosis and human immunodeficiency virus infection in developing countries. Lancet 1990; 335:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1194/abstract/75\">",
"      Steingart KR, Ng V, Henry M, et al. Sputum processing methods to improve the sensitivity of smear microscopy for tuberculosis: a systematic review. Lancet Infect Dis 2006; 6:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1194/abstract/76\">",
"      Hassim S, Shaw PA, Sangweni P, et al. Detection of a substantial rate of multidrug-resistant tuberculosis in an HIV-infected population in South Africa by active monitoring of sputum samples. Clin Infect Dis 2010; 50:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1194/abstract/77\">",
"      Bakari M, Arbeit RD, Mtei L, et al. Basis for treatment of tuberculosis among HIV-infected patients in Tanzania: the role of chest x-ray and sputum culture. BMC Infect Dis 2008; 8:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1194/abstract/78\">",
"      Garay SM. Tuberculosis and HIV infection. Semin Respir Crit Care Med 1995; 16:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1194/abstract/79\">",
"      Yajko DM, Nassos PS, Sanders CA, et al. High predictive value of the acid-fast smear for Mycobacterium tuberculosis despite the high prevalence of Mycobacterium avium complex in respiratory specimens. Clin Infect Dis 1994; 19:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1194/abstract/80\">",
"      Kivihya-Ndugga LE, van Cleeff MR, Githui WA, et al. A comprehensive comparison of Ziehl-Neelsen and fluorescence microscopy for the diagnosis of tuberculosis in a resource-poor urban setting. Int J Tuberc Lung Dis 2003; 7:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1194/abstract/81\">",
"      Shea YR, Davis JL, Huang L, et al. High sensitivity and specificity of acid-fast microscopy for diagnosis of pulmonary tuberculosis in an African population with a high prevalence of human immunodeficiency virus. J Clin Microbiol 2009; 47:1553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1194/abstract/82\">",
"      Schluger NW, Rom WN. The polymerase chain reaction in the diagnosis and evaluation of pulmonary infections. Am J Respir Crit Care Med 1995; 152:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1194/abstract/83\">",
"      Aceti A, Zanetti S, Mura MS, et al. Identification of HIV patients with active pulmonary tuberculosis using urine based polymerase chain reaction assay. Thorax 1999; 54:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1194/abstract/84\">",
"      Havlir DV, Barnes PF. Tuberculosis in patients with human immunodeficiency virus infection. N Engl J Med 1999; 340:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1194/abstract/85\">",
"      Boehme CC, Nicol MP, Nabeta P, et al. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet 2011; 377:1495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1194/abstract/86\">",
"      Small PM, Pai M. Tuberculosis diagnosis--time for a game change. N Engl J Med 2010; 363:1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1194/abstract/87\">",
"      Theron G, Pinto L, Peter J, et al. The use of an automated quantitative polymerase chain reaction (Xpert MTB/RIF) to predict the sputum smear status of tuberculosis patients. Clin Infect Dis 2012; 54:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1194/abstract/88\">",
"      Minion J, Leung E, Talbot E, et al. Diagnosing tuberculosis with urine lipoarabinomannan: systematic review and meta-analysis. Eur Respir J 2011; 38:1398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1194/abstract/89\">",
"      Shah M, Martinson NA, Chaisson RE, et al. Quantitative analysis of a urine-based assay for detection of lipoarabinomannan in patients with tuberculosis. J Clin Microbiol 2010; 48:2972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1194/abstract/90\">",
"      Talbot E, Munseri P, Teixeira P, et al. Test characteristics of urinary lipoarabinomannan and predictors of mortality among hospitalized HIV-infected tuberculosis suspects in Tanzania. PLoS One 2012; 7:e32876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/10/1194/abstract/91\">",
"      Peter JG, Theron G, van Zyl-Smit R, et al. Diagnostic accuracy of a urine lipoarabinomannan strip-test for TB detection in HIV-infected hospitalised patients. Eur Respir J 2012; 40:1211.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8021 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.131.240.2-13CD9D8202-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_10_1194=[""].join("\n");
var outline_f1_10_1194=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20477340\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Interactions between HIV and tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      - Effect of HIV on TB",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Effect of TB on HIV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Impact of antiretroviral therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1240930045\">",
"      - Effect on TB incidence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1240930352\">",
"      - Starting ART in TB patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Pulmonary tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Extrapulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5854742\">",
"      Subclinical infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      RADIOGRAPHIC IMAGING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Chest radiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Computed tomography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Abdominal imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Gallium scanning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5989329\">",
"      Tuberculin skin testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5989944\">",
"      Clinical specimens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5988868\">",
"      - Pulmonary specimens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Sputum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H5989513\">",
"      Bronchoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H5988963\">",
"      Thoracentesis and pleural biopsy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5990090\">",
"      - Other clinical specimens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H5990098\">",
"      Lymph node aspiration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H5990119\">",
"      Other sites",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5989552\">",
"      Diagnostic microbiology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5989892\">",
"      - Sputum smear and culture",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5989687\">",
"      - Fluorescence microscopy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5989914\">",
"      - Molecular tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H5989591\">",
"      Nucleic acid amplification assays",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H5989929\">",
"      Xpert MTB/RIF assay",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5149409\">",
"      - Urine antigen detection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Drug resistance testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/8021\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/8021|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?9/36/9807\" title=\"diagnostic image 1\">",
"      Chest x-ray - Tuberculosis and HIV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?32/48/33538\" title=\"diagnostic image 2\">",
"      Computed tomography - Tuberculous lymphadenopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/43/20154?source=related_link\">",
"      Approach to the HIV-infected patient with pulmonary symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/56/9098?source=related_link\">",
"      Diagnosis of pulmonary tuberculosis in HIV-negative patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/52/32586?source=related_link\">",
"      Diagnosis, treatment, and prevention of drug-resistant tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23098?source=related_link\">",
"      Immune reconstitution inflammatory syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/55/17272?source=related_link\">",
"      Monitoring the HIV-infected patient on antituberculous medications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/12/4298?source=related_link\">",
"      Treatment of latent tuberculosis infection in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/35/19002?source=related_link\">",
"      Treatment of pulmonary tuberculosis in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/47/22261?source=related_link\">",
"      Tuberculous pleural effusions in HIV-infected patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_10_1195="Dietary triggers migraine";
var content_f1_10_1195=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F73282&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F73282&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Dietary triggers for migraine headache",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Alcohol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chocolate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aged cheeses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Monosodium glutamate (MSG)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aspartame (Nutrasweet)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Caffeine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nuts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nitrites, nitrates",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_10_1195=[""].join("\n");
var outline_f1_10_1195=null;
var title_f1_10_1196="Periop hemostasis agents";
var content_f1_10_1196=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F68515&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F68515&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Perioperative management of agents affecting hemostasis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Name or class of drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical considerations",
"       </td>",
"       <td class=\"subtitle1\">",
"        Recommended strategy for surgery with brief NPO state",
"       </td>",
"       <td class=\"subtitle1\">",
"        Recommended strategy for surgery with prolonged NPO state",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aspirin and dipyridamole",
"       </td>",
"       <td>",
"        <p>",
"         Continuation may cause perioperative hemorrhage.",
"        </p>",
"        <p>",
"         Discontinuation may increase the risk of vascular complications.",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Continue for surgeries where patients are at high risk for perioperative vascular complications and morbidity related to perioperative hemorrhage is not significant.",
"        </p>",
"        <p>",
"         Discontinue for surgeries where perioperative bleeding could be catastrophic as in CNS surgery. If decision is made to stop, discontinue aspirin 7 to 10 days before surgery and discontinue dipyridamole at least&nbsp;two days before surgery.",
"        </p>",
"       </td>",
"       <td>",
"        Resume with oral intake.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        P2Y12 receptor blockers(clopidogrel, prasugrel, ticlopidine, ticagrelor)",
"       </td>",
"       <td>",
"        When used after cardiac stenting procedure, if discontinued can cause cardiac ischemia perioperatively. If continued can result in bleeding complications.",
"       </td>",
"       <td>",
"        Ideally elective procedures should be delayed until the mandatory period of platelet inhibition with these agents is completed. When used for long-term stroke prophylaxis, should be discontinued 7 to 10 days.",
"       </td>",
"       <td>",
"        Resume with oral intake.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Warfarin",
"       </td>",
"       <td colspan=\"3\">",
"        See \"Management of anticoagulation before and after elective surgery\"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dabigatran",
"       </td>",
"       <td colspan=\"3\">",
"        See \"Management of anticoagulation before and after elective surgery\"",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_10_1196=[""].join("\n");
var outline_f1_10_1196=null;
var title_f1_10_1197="Nail questionnaire";
var content_f1_10_1197=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F85548&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F85548&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Key questions for the patient with abnormal nails",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        What do you think is the cause of your nail problem?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Were you born with this problem? If no, when did this problem begin?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Which nails were affected first?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Which nails are affected now?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        How has your nail condition progressed?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Using general terms, describe your nails (hard, soft, brittle, etc)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Have you ever traumatized any of the involved nails?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Do you do anything to affect your nails or the tips of your fingers or toes?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Do any of your hobbies affect or traumatize your nails (ie, tennis, jogging, basketball, racquetball, painting, playing the piano, etc)?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        What is your occupation?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Have you done any of the following: Picked at your nails, bit or sucked on your nails, torn your nails off, worn tight or pointed-toe shoes, or pushed the cuticle back? If yes, when and how often?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Have you ever had ingrown nails?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Are your hands in water often?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Do your nails ever come in contact with any chemicals or irritants such as strong soaps, detergents, hair color/straightening chemicals, or dyes?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        What nail cosmetics or conditioners do you use (ie, base coat, top coat, enamel, nail strengtheners, nail hardeners, cuticle treatment, gloss, nail conditioners, etc)?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Do you go to a manicurist/pedicurist? How often? What do you usually have done to your nails?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Have you ever had any of the following: Sculptured nails, false/artificial nails, gel nails, nail tips, nail wraps, acrylic nails, etc? If so, how often and when was the last time?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        What instruments do you use when caring for your nails?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        How do you use your nail care instruments?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        How often do you use your nail care instruments?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Have you recently experienced swelling around the cuticles?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        What treatments have you tried for your nail problem? Please list all pills, topical treatments, and surgical treatments and the dates.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Do you currently have, or have you ever had, any other skin or hair problems (ie, lichen planus, psoriasis, alopecia areata, ringworm, jock itch, athlete's foot, vaginal yeast infection or other yeast infection, etc)?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Do you currently have, or have you ever had, any other medical problems (ie, diabetes mellitus, heart trouble, lung issues or difficulty breathing, kidney problems, thyroid problems, gastrointestinal disorders, lower extremity swelling, etc)?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Is there any chance that you could be pregnant?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        What prescription and nonprescription medications have you taken during the last year? Please include vitamins and herbal supplements.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Do you have any drug allergies?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Does anyone in your family have any of the following: Nail problems, thyroid problems, diabetes, hair and skin problems (ie, psoriasis, lichen planus, fungus, etc)?",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_10_1197=[""].join("\n");
var outline_f1_10_1197=null;
var title_f1_10_1198="Vitamin D synthesis";
var content_f1_10_1198=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F63249&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F63249&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Vitamin D metabolism",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 441px; height: 378px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Metabolic activation of vitamin D to calcitriol and its effects on calcium and phosphate homeostasis. The result is an increase in the serum calcium and phosphate concentrations.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_10_1198=[""].join("\n");
var outline_f1_10_1198=null;
var title_f1_10_1199="Transverse patella fracture oblique view";
var content_f1_10_1199=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F82192&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F82192&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Transverse patella fracture from an oblique view",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 362px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This plain radiograph, taken from an oblique view, shoes and transverse patella fracture (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jim Blount, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_10_1199=[""].join("\n");
var outline_f1_10_1199=null;
